

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

BMJ Open

Wilson Disease in the US - Epidemiology and Real-World Patient Characteristics Based on a Claims Database Study

Journal:	BMJ Open
Manuscript ID	bmjopen-2024-089032
Article Type:	Original research
Date Submitted by the Author:	20-May-2024
Complete List of Authors:	Fang, Shona; Alexion Pharmaceuticals Inc Strader, Carey; Cerner Enviza LLC, Costantino, Halley; Cerner Enviza LLC Weiss, Karl Heinz; Salem Hospital Hedera, Peter; University of Louisville
Keywords:	Prevalence, EPIDEMIOLOGY, Cross-Sectional Studies, Chronic Disease

SCHOLARONE[™] Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

terez oni

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies



Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

3	
4	
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
32 33	
33 34	
34 35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	

1 2

1

2

3

4

9

Wilson Disease in the US - Epidemiology and Real-World Patient **Characteristics Based on a Claims Database Study**

Shona Fang, ScD¹ Carey Strader,² Halley Costantino,² Karl Heinz Weiss, MD³ Peter Hedera, MD,

5 PhD⁴

6 ¹Alexion, AstraZeneca Rare Disease, Boston, MA; ²Cerner Enviza, an Oracle company, Kansas City,

7 MO; ³Salem Medical Center, Heidelberg, Germany; ⁴University of Louisville, Louisville, KY

ORCID: Peter Hedera 0000-0003-2699-4085, Halley Costantino 0009-0000-6658-6057 8 JJ

10 **Corresponding author:**

11 Shona Fang, ScD

12 121 Seaport Avenue

13 Boston, MA 02210

14 shona.fang@alexion.com

15 **Word count: 3,648**

Running title: Epidemiology of Wilson Disease in the US 16

17 Financial Disclosure/Conflict of Interest concerning the research related to the manuscript: CS and

18 HC declare being employees of Cerner Enviza, an Oracle company, which received funding from

19 Alexion Pharmaceuticals to conduct this study. PH has no financial relationships to disclose. KHW

20 declares no conflicts of interest that pertains to this work. SF is an employee of Alexion, AstraZeneca

21 Rare Disease and may own stock in AstraZeneca.

22 Funding Sources for study: This study was funded by Alexion Pharmaceuticals.

2		
3 4	23	Abstract
5 6	24	Objectives: To describe the epidemiology, patient characteristics and comorbidities in patients with
7 8 9	25	Wilson disease (WD) in the US.
10 11 12	26	Design: Retrospective, population-based study
13 14	27	Setting: The study used the US Komodo claims database containing records regarding medical claims
15 16 17	28	for over 120 million individuals.
17 18 19	29	Participants: Patients with WD were identified via ICD10 code during the study period 2016–2019. A
20 21	30	further stratification by disease subtype (hepatic, neurologic and psychiatric) was performed.
22 23 24	31	Main outcome measures: WD prevalence was reported by age, sex, and US census regions/divisions.
25 26	32	Adjusted prevalence was calculated using age-specific prevalence standardized to the US (2010 US
27 28	33	census) and to the world (WHO 2000–2025) to enable comparisons across countries, using direct
29 30 31	34	standardization of prevalence estimates by age group.
32 33	35	<i>Results:</i> Overall, 2,115 WD patients were identified during the study period. Among them, 56.8% had
34 35	36	hepatic, 57.0% neurologic and 47.4% psychiatric signs and symptoms. The most frequent
36 37 38	37	manifestations in hepatic patients were liver signs and symptoms (90.8%), in neurologic patients
38 39 40	38	cognitive defects (50.7%), and in psychiatric patients mood disorders (86.4%). The mean age in the
41 42	39	overall cohort was 39.9 years. Prevalence estimation was based on 1,481 WD patients between 2017
43 44	40	and 2019. The 2017–2019 crude period prevalence was 21.2 patients per million (95% confidence
45 46	41	interval: 20.1–22.3), with similar prevalence observed for both sexes.
47 48 40	42	Conclusions: This study provides important real-world data on the diagnosed prevalence of WD in the
49 50 51	43	US and revealed the comorbidities associated with various disease subtypes, thereby providing a
52 53	44	comprehensive basis for guiding physicians and policy makers in the management of this chronic
54 55 56 57 58	45	disease.

1 2	
3 46 4	Strengths and limitations of this study
5 6 47	• This study estimated the diagnosed prevalence of WD for the first time in the US, by using a
7 8 48	large, nationally representative claims database. The real-world nature of the data helps
9 10 49 11	estimate the observed frequency of Wilson disease in the US using ICD-10 codes specific to
12 50 13	WD.
14 51 15	• The classification of patients into subtypes, and especially the novel approach to differentiate
16 52 17 52	psychiatric symptoms from neurological symptoms, was a further strength of this study.
18 19 53	• Besides general limitations inherent to claims data, the limitations specific to this study
20 21 54	included a limited study period after the introduction of a new WD-specific ICD-10 code in
22 23 55	2015.
24 25 56	• The used claims data did not capture information on OTC medications and the treated patients
26 27 57 28	represented the proportion of patients with prescription treatment only.
29 58 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 59	

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open

Introduction Wilson disease (WD) is an autosomal recessive condition which leads to an excessive copper deposition in body organs, particularly in the liver and the central nervous system.¹ This genetic disorder is caused by mutations of the P-type ATPase copper transporter ATP7B gene located in the human chromosome 13.² To date, more than 600 variants in the ATP7B gene have been described, and most WD patients are compound heterozygous with two different ATP7B variants, complicating and prolonging genetic WD diagnosis.³ WD generally presents in childhood and young adulthood with the most common age of presentation between 10 and 20 years, though patients can occasionally present before the age of 5 years and after the age of 70 years.⁴ Clinical presentation of WD includes a combination of hepatic, neurologic, psychiatric, and ophthalmologic symptoms. Psychiatric symptoms often precede the diagnosis of WD and include

personality changes, depression, cognitive changes, and anxiety.⁵ The neurologic symptoms of WD mostly refer to dysfunction in the extrapyramidal system including dysarthria, dystonia, gait abnormalities, tremor, parkinsonism, chorea, and seizures.⁶ Psychiatric symptoms have been only recently recognized as independent manifestations of WD, as it was previously assumed that they occur together with neurological symptoms, and patients were often referred to as having neuro-psychiatric disorders.⁷ The symptoms related to hepatic dysfunction in WD can range from an asymptomatic increase in liver enzyme levels to severe liver failure. Typically, early on in disease progression there is a mild increase in transaminases, which then may progress to chronic active hepatitis, followed by fibrosis and cirrhosis.⁸

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

WD is a rare disease with recent worldwide clinical prevalence estimates ranging from approximately 16.7 to 25 patients per million,⁹ although the prevalence can vary across countries and may be higher in selected regions such as in some Asian communities.¹⁰ Interestingly, there is a discrepancy of WD prevalence estimates originating from epidemiological compared to genetic studies and recent genetic data with a considerably higher prevalence (139 per million) indicate that the prevalence of WD may be underestimated.¹¹ The possibility of underdiagnosis, misdiagnosis and the lack of accounting for incomplete variant penetrance in the genetic calculations were hypothesized as the main reasons for

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

the observed inconsistency between genetic vs. clinical data.^{11,12} For the US, population-based
epidemiological data are still scarce. A previous study reported a genetic birth prevalence of 18.2 per
million births,¹³ and an abstract on cardiac manifestations in WD reported a prevalence of 26 patients
per million, but no details of methodology.¹⁴

Thus, large population-based studies assessing the epidemiology of WD and its subtypes in the US are needed, allowing for a greater characterization around the spectrum of disease severity and the diagnosed prevalence of WD. Here we present the US-specific data from a recently completed multicountry real-world evidence study that used claims data to investigate various aspects of WD in a reallife setting including epidemiology and patient demographic and clinical characteristics.

95 Methods

96 Study design

This retrospective, population-based observational study used health insurance claims data to assess WD epidemiology and patient characteristics using the US Komodo Health claims database available from 2012–2020.¹⁵ Komodo's private payor-complete database contains records regarding prescription and/or medical claims for over 120 million individuals, collected from more than 150 private insurers in the US, including Medicaid managed-care and Medicare Advantage plans. This study used the closed claims available in the database. Closed claims come directly from the payer and provide the complete patient journey, such as full medical and/or prescription benefit information including insurance eligibility.

105 Population

Patients were selected based on their first reported WD diagnosis (index event) in the claims database
between 2016 and 2019 (study period). The diagnosis was based on code (ICD-10 code E83.01 or
ICD-9-CM code 275.1 prior to October 1, 2015). The standard ICD-9 diagnostic code for WD could
also include another rare condition called Menkes disease. The WD-specific ICD-10 code (E83.01)
was introduced in the US on October 1, 2015. A WD diagnosis was defined as at least one inpatient or
two outpatient visits with a WD ICD-10 code, separated by at least 30 days during the study period.

Page 7 of 26

BMJ Open

112 No age restriction was imposed. Patients were excluded from the study if they had at least one 113 prescription for a copper replacement drug during the study period. This was applied to rule out 114 patients with Menkes disease which is treated by copper replacement drugs.

Cohorts and subgroups

The cohort presented here includes patients that fulfilled the criteria for at least one WD diagnosis at any time during the study period (2016–2019) and a continuous enrollment for at least one calendar year before the index event. Separately, prevalence was assessed in the period between 2017 and 2019 for patients that had a history of at least one WD diagnosis at any time during that period and a continuous enrollment for at least two calendar years. This separate assessment period for prevalence estimation was based on the WD-specific diagnosis code becoming effective in the US only in 2015. Due to the possibility of miscoding, the most accurate prevalence estimation of WD can be made between 2017 and 2019, as this period includes at least one full calendar year since the introduction of the new code.

A further stratification by WD subtypes was performed. The subtypes "hepatic", "neurologic" and "psychiatric" were not mutually exclusive or strictly delineated but were based on the presence of signs and symptoms. Patients were assigned to the hepatic subtype if they were diagnosed with liver signs and symptoms, acute hepatitis (not viral), cirrhosis (decompensated or compensated), liver failure, portal hypertension, or hepatocellular carcinoma. Patients assigned to the neurologic subtype had a diagnosis for tremor, parkinsonism or akinetic rigid syndrome, gait abnormalities/ataxia, dysarthria, dystonia, chorea, dysphagia, myopathy, seizures, migraine, somatoform autonomic dysfunction or cognitive disorder. Patients diagnosed with mood disorders, paranoia/schizophrenia, psychosis, or personality disorders were assigned to the psychiatric subtype. WD manifestations were defined as the occurrence of specific signs or symptoms associated with each of the subtypes and were identified using respective ICD-10 codes (see Supplementary Tables 1-3).

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

136 Variables

Data on patient characteristics (age, sex, region of residence), physician specialty, proportion of
patients never treated, distribution of subtypes and manifestations were ascertained at baseline.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Comorbidities were assessed during the study period (2016–2019). Overall, age-, sex-, and regionspecific prevalence (crude and age-adjusted period prevalence) were assessed in the period between 2017 and 2019. The rationale for considering a period prevalence rather than an annual prevalence was that the identification of WD patients was based on ICD-10 codes, without considering WD treatment or laboratory records, and the assumption that WD patients who are well managed using over the counter (OTC) or prescription medication may not necessarily visit a health care provider (HCP) each year.

146 Data analysis

Descriptive statistics were calculated for demographic and baseline characteristics (overall and by subtype). Means and standard deviations (SDs) were provided for continuous or discrete data. Frequencies and percentages were provided for categorical data. For WD manifestations, the frequencies of occurrence of specific ICD-10 codes within subtypes and within the overall patient cohort were calculated and the three most frequent manifestations were listed by subtype. For comorbidities, all recorded diagnoses (ICD-10 codes level-3) at any time during the study period were ranked according to frequency and a list of the 10 most frequent comorbidities in the overall cohort were reported. In addition, the Charlson Comorbidity index (CCI; version of 2011), an assessment tool designed to predict mortality in patients with multiple comorbidities,¹⁶ was assessed for each patient and a mean score including SD (higher scores indicating greater mortality risk and more severe comorbid conditions) was calculated for the overall cohort. Crude period prevalence was calculated from the number of WD cases identified and was expressed as patients per million including 95% confidence intervals (CI). The denominator was the number of patients with continuous enrollment spanning the period of interest (2017–2019) and the numerator was any patient from the denominator with at least one WD diagnosis claim during the period of interest. Prevalence was reported by age, sex, and US census regions/divisions. Adjusted prevalence was calculated using age-specific prevalence standardized to the US (2010 US census) and to the world (WHO 2000-2025) to enable comparisons across countries, using direct standardization of prevalence estimates by age group.

BMJ Open

Ethics statement The final protocol, any amendments, and informed consent documentation of this study were reviewed and approved by an institutional review board (IRB) and/or independent ethics committee (IEC) for each country participating in the study. The IRB for the US was Pearl Pathways. The study was conducted in accordance with legal and regulatory requirements, as well as with scientific purpose, value and rigor, and followed generally accepted research practices described in Good Pharmacoepidemiology Practices guidelines issued by the International Society for Pharmacoepidemiology. Data availability statement The data that support the findings of this study are available from Komodo Health. Restrictions apply to the availability of these data, which were used under license for this study. Access to data must be requested through Cerner Enviza. **Results** WD subtypes and manifestations The observed cohort included 2,115 WD patients identified between 2016 and 2019. Among these, more than half had hepatic and/or neurologic symptoms (56.8% and 57.0%, respectively) and around half had psychiatric symptoms (47.4%). Most patients had overlapping subtypes, presenting concomitantly with hepatic, neurologic, and/or psychiatric symptoms. Figure 1 illustrates the distribution of sex (a) and age (b) within subtypes. Slightly more male than female patients had neurologic (54.6%) and psychiatric (55.6%) symptoms, whereas the gender distribution was equal in the hepatic subtype. With regards to age distribution, most patients in all subtypes were in the age groups between 18 to 39 years and 40 to 64 years. The distribution of young (0-17 years) and older (above 65 years) patients was also similar between subtypes, though there were slightly more older patients in the neurologic subtype (21% vs. 16% [hepatic] and 17% [psychiatric]). The most frequent manifestations associated with the different subtypes and their proportion in the

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

190 overall cohort are highlighted in **Table 1**. Hepatic patients most frequently experienced liver signs and

191 symptoms (90.8%), cirrhosis (37.9%) and hepatitis (28.9%). Neurologic patients most frequently

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

experienced cognitive defects (50.7%), ataxia and gait abnormalities (36.2%) and dysphagia (27.2%).
Psychiatric patients most frequently experienced mood disorders (86.4%), a mix of symptoms in

194 children (22.3%) and paranoia/schizophrenia (19.8%).

Baseline characteristics

Selected baseline characteristics of the overall cohort and by subtype are displayed in Table 2. The mean age in the overall cohort was 39.9 years (SD=20.1 years). The lowest mean age was reported for the psychiatric subtype (39.2 years, SD=20.2 years) and the highest for the neurologic subtype (42.3 years, SD=20.7 years). Overall, 51.8% were male patients. A larger portion of patients came from the South (30.6%) and fewer from the Northeast (21.8%) with little difference between subtypes. While for a majority (54.2%) of overall WD cases no information was available regarding the specialists managing the primary WD diagnosis, the available results showed that patients were mostly in the care of gastroenterologists (13.2%) and general/family practitioners (12.6%). Hepatic patients were more frequently seen by gastroenterologists (16.4%), as compared to the other subtypes (9.7% of neurologic patients and 9.0% of psychiatric patients). On average, patients were followed up for 2.2 years (SD=1.3 years) with little difference between subtypes. Among all patients, the majority (83.0%) were never treated with a reimbursable WD prescription medication during the study period.

208 Comorbidities

WD patients were diagnosed with a broad spectrum of comorbidities. The most common clinical conditions diagnosed during the study period included other joint disorders (50.9%), unspecified soft tissue disorders (49.3%), dorsalgia (49.1%), disorders of lipoprotein metabolism and other lipidemias (45.9%), essential hypertension (45.2%), anxiety disorders (42.9%), and other diseases of liver (40.0%), **Figure 2**. The extent of comorbidities was also reflected by a mean CCI score of 1.92 (SD=2.68).

Prevalence

Prevalence estimation was based on 1,481 WD patients between 2017 and 2019. The 2017–2019 crude

217 period prevalence was 21.2 patients per million (95% CI: 20.1–22.3), with similar prevalence

observed for both sexes (male: 21.2 per million, 95% CI: 19.7–22.8 and female: 21.1 per million, 95%

BMJ Open

CI: 19.7–22.6), Table 3. The crude period prevalence peaked among young adults in the 18 to 39
years age group (27.1 per million, 95% CI: 24.7–29.5), followed closely by adults 40 to 64 years old
(26.1 per million, 95% CI: 24.0–28.2). The highest crude period prevalence was recorded in the
Northeast (24.1 per million, 95% CI: 21.6–26.7), followed by the Midwestern (22.2 per million, 95%
CI: 19.9–24.5), Western (21.6 per million, 95% CI: 19.2–24.0), and Southern (18.4 per million, 95%
CI: 16.7–20.1) regions of the US.

Adjusted period prevalence was calculated using age-specific prevalence standardized to the US (2010 US census) and to the world (WHO 2000–2025). Between 2017 and 2019, both the US-adjusted and WHO-adjusted period prevalences were similar (22.0 per million, 95% CI: 20.9–23.1 and 21.4 per million, 95% CI: 20.4–22.5, respectively) to the crude period prevalence observed in this study.

Discussion

Principal findings and implications

There is a gap of knowledge regarding the epidemiology and clinical characteristics of WD patients
from a national and international perspective. In this large population-based study we assessed WD
patient characteristics and epidemiology in the US.

Approximately two-thirds of the cohort showed hepatic and/or neurologic symptoms, which is consistent with the natural disease course, as WD mostly affects the liver and brain.¹⁷ Typically, hepatic symptoms precede the onset of neurologic symptoms and may thus be diagnosed at a younger age². In line with this, though not as evident in the age distribution by subtypes, the mean age at index in the hepatic subtype was slightly lower compared to the neurologic subtype. In agreement with our data on gender distribution in the neurologic and psychiatric subtypes, a registry-based study observed that the neuropsychiatric WD form occurred more frequently in men (67%) vs. women (49%).¹⁸

241 Our results also revealed the extent of comorbidities associated with various disease subtypes, as some

of the most frequently reported manifestations were quite severe (e.g., around 40% of patients in the

hepatic subtype presented with cirrhosis). The frequency of hepatic, neurologic, and psychiatric

⁵⁹ 244 presentations, as well as the manifestations within these subtypes varies considerably in other Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

published studies.⁴ Considering the great variability in WD symptoms, it is likely that there is referral
bias. A review of several independent case series suggested that dysarthria, gait abnormality/ataxia and
dystonia are the most frequent manifestations in the neurologic subtype, which partially reflects our
findings.⁴ The higher rates of dystonia and dysarthria reported in the literature may be explained by the
fact that only symptomatic conditions that require treatment get captured in the claims under the ICD10 diagnosis code. Furthermore, a study from China reported distributions of hepatic manifestations
(e.g., 22% cirrhosis and 11% cirrhotic complications) which were similar to our findings.¹⁹

WD patients in our study were in the typical age range for first symptom onset and disease progression (between the second and sixth decade of life). We found a slightly lower mean age in the psychiatric subtype compared to the other subtypes, which might reflect that psychiatric manifestations are often the first symptoms.⁷ The earlier diagnosis of psychiatric WD may highlight a critical gap in care for these patients, as neurologic and psychiatric involvements have been previously assessed in tandem, with neurologic symptoms becoming more apparent later in life. Given the recessive nature of WD, the results confirmed the expectation of a relatively even distribution of cases across genders, which also aligns with previous studies conducted in France,²⁰ and Hong Kong.¹⁹ The geographical distribution within the US, with a larger portion of patients coming from the South and fewer from the Northeast, might correspond to the distribution of major university centres in the US where WD patients are typically diagnosed. Given the nature of the disease, it is not surprising that patients were primarily in the care of gastroenterologists (most pronounced in hepatic patients), though a considerable fraction of patients was also diagnosed or treated by general or family practitioners who might be the first contact points. The high rate of patients never treated with a reimbursable WD medication during the study period was likely due to the use of OTC zinc preparations which are not covered by insurers in the US, the refusal to take medications and rely solely on a low-copper diet, or the hypothesis that some physicians used the WD diagnosis code to initiate further testing for the patients but did not prescribe a WD medication at that initial stage. Further investigation on this aspect is warranted given the chronic nature of this disease.

Page 13 of 26

BMJ Open

Furthermore, our results demonstrated that WD patients were diagnosed with a broad spectrum of comorbidities, most frequently affecting joints, soft tissues, and the cardiovascular system, as well as pain symptoms and metabolic disorders. Comorbidities of WD are rarely described in the literature and vary considerably, however, our findings are at least partially consistent with comorbidities reported in the literature. Kruger et al and Dziezyc et al described that the most common complications in WD patients were pain, renal, neurologic, cardiac, skin, osteoarticular, or endocrinologic complications and included other organ disturbances. ^{21,22}

Only a few population-based studies assessing WD epidemiology have been performed to date world-wide. It is challenging to compare the results from this study to other reports, because of the heterogeneity of the disease and of the heterogeneity in population, diagnosis, and methodologies employed in other studies assessing WD epidemiology. However, the observed prevalence estimates (US-adjusted prevalence: 22.0 patients per million) align well within the WD prevalence range reported in other claims-based studies in France (15 per million), ²³ and China (17.9 per million), ¹⁹ while estimates from a claims-based study in South Korea were slightly higher (38.7 per million).²⁴ Two recent systematic literature reviews assessed WD prevalence data originating from populationbased epidemiological as well as genetic studies.^{11,25} Sandahl et al. reported a crude population-based prevalence between 25 and 34.5 per million,²⁵ and underlined that specific populations in Croatia, Sardinia, Israel, Costa Rica, Middle Eastern countries, Pakistan and India had considerably higher prevalence estimates, either related to consanguinity or higher mutation frequencies. Gao et al. performed a meta-analysis resulting in a pooled population-based prevalence of 14 patients per million.¹¹ Both reviews mentioned that at least in some studies a higher genetic vs. clinically based prevalence could be observed. Gao et al. reported a pooled prevalence at birth of 127 per million.¹¹ Overall, it seems evident that many factors such as the still uncertain mutational spectrum and penetrance of WD variants, the unclear effect of combined mutations and epigenetic factors, methodological differences in studies, underdiagnosis, changes in diagnostic awareness and treatment options over time, as well as geographic factors may influence WD prevalence estimates. Thus, it is important to assess epidemiological data from large, population-based studies, as the one presented here.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

299 Strengths and limitations

This study benefitted from several strengths. Data elements extracted from claims, some of which are not generally available in literature or patient registries, are collected routinely in clinical practice and represent real-world activities and outcomes. The real-world nature of the data helps estimate the observed frequency of diagnosed diseases using ICD-10 codes. The ICD-10 codes for WD are highly specific, despite any limitations in coding or misdiagnosis which may occur. The Komodo claims data have a large number of patients and are nationally representative based on comparisons made to the US census estimates (by age, sex, and region). The closed claims provide a longitudinal history that facilitates the analysis of the natural history of the disease, healthcare utilization, and treatment dynamics. Of note, the crude prevalence observed in this study between 2017 and 2019 was comparable to the US age-standardized adjusted results, reaffirming the representativeness of the Komodo data for rare disease research in the US. The classification of patients into subtypes, and especially the novel approach to differentiate psychiatric symptoms from neurological symptoms, was a further strength of this study.

There are some general limitations inherent to claims data, such as the potential for errors in diagnosis coding or record keeping at the point of the HCP. Since claims data are used for billing purposes, they only include records for the insured population, therefore projections of the US population assume similarities between the insured and uninsured patients. Leveraging secondary data requires an algorithm for case identification and validated algorithms specific to WD do not currently exist. Claims data contain only reimbursed medical services and thus e.g., results of lab tests or patientreported outcomes are not captured.

320 In addition, there were some limitations specific to this study. Epidemiological trends over time were
 321 hard to assess given the limited study period and the introduction of the new WD-specific ICD-10

322 code. Only symptomatic conditions were captured under the ICD-10 code; therefore, no inferences can

be made regarding pre-symptomatic patients with WD. The used claims data did not capture

 $\frac{1}{2}$ 324 information on OTC medications and the treated patients represented the proportion of patients with

prescription treatment only.

1

2 3	
4	32
5 6	32
7 8	32
9 10	32
11 12	33
13 14	33
15 16	55
17 18	
19 20	
21 22	
23	
24 25	
26 27	
28 29	
30 31	
32 33	
34 35	
36	
37 38	
39 40	
41 42	
43 44	
45 46	
47	
48 49	
50 51	
52 53	
54 55	
56 57	
58	
59 60	

Conclusions 6

27 This claims study provides important real-world data on the prevalence of WD in the US and revealed 8 the extent of comorbidities associated with various disease subtypes. The results of this study extend 9 existing research findings and provide a comprehensive epidemiological basis for guiding physicians .ge. 0 and policy makers in the management of this chronic disease.

1 2		
3 4	332	Declarations
5 6 7	333	Acknowledgments
7 8 9	334	Medical writing was provided by Dr. Sophia von Stockum of ZEG – Berlin Center for Epidemiology
10 11	335	and Health Research GmbH with editorial input from all authors.
12 13 14	336	Authors' Contributions
15 16	337	SF, CS, KHW and PH were responsible for the design, writing and editing of the final version of the
17 18	338	manuscript. SF, CS and HC were responsible for the execution of the study and HC was responsible
19 20	339	for the analysis of the data. All authors had critically reviewed the manuscript and approved its final
21 22 23	340	version.
24 25	341	Financial Disclosures of all authors (for the preceding 12 months)
26 27	342	PH has no financial relationships to disclose. KHW advises for Alexion, Univar, Orphalan, Desitin,
28 29	343	Tilomed, Ultragenyx, Pfizer, Vivet therapeutics, Abbvie. HC is an employee of Cerner Enviza, an
30 31 32	344	Oracle company, which has provided consultancy for Alexion Pharmaceuticals.
33 34 35	345	Financial Disclosures
36 37	346	PH has no financial relationships to disclose. KHW declares no conflicts of interest that pertains to
38 39	347	this work. SF is an employee of Alexion, AstraZeneca Rare Disease and may own stock in
40 41	348	AstraZeneca.
42 43 44	349	AstraZeneca.
45 46 47	350	
48 49 50	351	
51 52 53	352	
54 55	353	
56 57 58 59 60	354	

2			
3 4	255	D	eferences
4 5	355		CICICIICES
6	356	1	Moini M, To U, Schilsky ML. Recent advances in Wilson disease. Transl Gastroenterol Hepatol
7	357		2021; 6:21. https://doi.org/10.21037/tgh-2020-02.
8	358	2	Kasztelan-Szczerbinska B, Cichoz-Lach H. Wilson's Disease: An Update on the Diagnostic
9	359		Workup and Management. J Clin Med 2021; 10(21). <u>https://doi.org/10.3390/jcm10215097</u> .
10	360	3	Ferenci P. Regional distribution of mutations of the ATP7B gene in patients with Wilson disease:
11	361		impact on genetic testing. Hum Genet 2006; 120(2):151–59. https://doi.org/10.1007/s00439-006-
12 13	362		<u>0202-5</u> .
13	363	4	Mulligan C, Bronstein JM. Wilson Disease: An Overview and Approach to Management. Neurol
15	364		Clin 2020; 38(2):417–32. https://doi.org/10.1016/j.ncl.2020.01.005.
16	365	5	Akil M, Schwartz JA, Dutchak D, Yuzbasiyan-Gurkan V, Brewer GJ. The psychiatric
17	366		presentations of Wilson's disease. J Neuropsychiatry Clin Neurosci 1991; 3(4):377–82.
18	367		https://doi.org/10.1176/jnp.3.4.377.
19	368	6	WILSON SAK. PROGRESSIVE LENTICULAR DEGENERATION: A FAMILIAL NERVOUS
20	369		DISEASE ASSOCIATED WITH CIRRHOSIS OF THE LIVER. Brain 1912; 34(4):295–507.
21 22	370		https://doi.org/10.1093/brain/34.4.295.
22	371	7	Zimbrean PC, Schilsky ML. Psychiatric aspects of Wilson disease: a review. Gen Hosp Psychiatry
24	372		2014; 36(1):53–62. https://doi.org/10.1016/j.genhosppsych.2013.08.007.
25	373	8	Boga S, Ala A, Schilsky ML. Hepatic features of Wilson disease. Handb Clin Neurol 2017;
26	374	-	142:91–99. https://doi.org/10.1016/B978-0-444-63625-6.00009-4.
27	375	9	Sandahl TD, Ott P. Epidemiology of Wilson Disease. In: Weiss K-H, Schilsky ML. Eds. Wilson
28	376	-	disease. Pathogenesis, molecular mechanisms, diagnosis, treatment and monitoring. Amsterdam:
29	377		Academic Press, 2018; p85–94.
30 31	378	10	Yamaguchi H, Nagase H, Tokumoto S, et al. Prevalence of Wilson disease based on genome
32	379	10	databases in Japan. Pediatrics international : official journal of the Japan Pediatric Society 2021;
33	380		63(8):918–22. <u>https://doi.org/10.1111/ped.14565</u> .
34	381	11	Gao J, Brackley S, Mann JP. The global prevalence of Wilson disease from next-generation
35	382		sequencing data. Genet Med 2019; 21(5):1155–63. https://doi.org/10.1038/s41436-018-0309-9.
36	383	12	Coffey AJ, Durkie M, Hague S, et al. A genetic study of Wilson's disease in the United Kingdom.
37	384		Brain 2013; 136(Pt 5):1476–87. https://doi.org/10.1093/brain/awt035.
38	385	13	Olivarez L, Caggana M, Pass KA, Ferguson P, Brewer GJ. Estimate of the frequency of Wilson's
39 40	386	10	disease in the US Caucasian population: a mutation analysis approach. Annals of human genetics
40 41	387		2001; 65(5):459–63. <u>https://doi.org/10.1046/j.1469-1809.2001.6550459.x</u> .
42	388	14	Li XJ, Tunio NA, Rana MN, Al-Kindi S, Mansoor E, Sclair S. S1095 Prevalence of Cardiac
43	389		Diseases in Wilson's Disease: A National, Population-Based Study. Am J Gastroenterol 2020;
44	390		115(1):S553-S553. <u>https://doi.org/10.14309/01.ajg.0000706428.74725.f8</u> .
45	391	15	Komodo Health. https://www.komodohealth.com/ (accessed Sep 13, 2023).
46	392		Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and
47	393	10	score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J
48 49	394		Epidemiol 2011; 173(6):676–82. https://doi.org/10.1093/aje/kwq433.
49 50	395	17	Członkowska A, Schilsky ML, eds. Handbook of Clinical Neurology : Wilson Disease. Elsevier,
51	396	17	2017.
52	397	18	Litwin T, Gromadzka G, Członkowska A. Gender differences in Wilson's disease. Journal of the
53	398	10	Neurological Sciences 2012; 312(1-2):31–35. https://doi.org/10.1016/j.jns.2011.08.028.
54	398 399	10	Cheung K-S, Seto W-K, Fung J, Mak L-Y, Lai C-L, Yuen M-F. Epidemiology and natural history
55	400	19	of Wilson's disease in the Chinese: A territory-based study in Hong Kong between 2000 and 2016.
56	400		World J Gastroenterol 2017; 23(43):7716–26. https://doi.org/10.3748/wjg.v23.i43.7716.
57 58	401	20	Poujois A, Woimant F. Wilson's disease: A 2017 update. Clinics and research in hepatology and
58 59	402	20	gastroenterology 2018; 42(6):512–20. https://doi.org/10.1016/j.clinre.2018.03.007.
60	403		$gasa o chiero logy 2010, 42(0).512-20. \underline{https://doi.org/10.1010/j.chille.2010.05.00/}{.}$


2			
3	404	21	Kruger E, Nedzesky J, Thomas NA, Cataldo J. PRO72 Common and Serious Comorbidities
4	405		Among Adults with Wilson Disease. Value in Health 2021; 24:S211.
5	406		https://doi.org/10.1016/j.jval.2021.04.1057.
6	407	22	Dzieżyc K, Litwin T, Członkowska A. Other organ involvement and clinical aspects of Wilson
7	408		disease. Handb Clin Neurol 2017; 142:157–69. https://doi.org/10.1016/B978-0-444-63625-
8 9	409		6.00013-6.
9 10	410	23	Poujois A, Woimant F, Samson S, Chaine P, Girardot-Tinant N, Tuppin P. Characteristics and
11	411	25	prevalence of Wilson's disease: A 2013 observational population-based study in France. Clinics
12	412		and research in hepatology and gastroenterology 2018; 42(1):57–63.
13	412		https://doi.org/10.1016/j.clinre.2017.05.011.
14		24	
15	414	24	Choe EJ, Choi JW, Kang M, et al. A population-based epidemiology of Wilson's disease in South
16	415		Korea between 2010 and 2016. Sci Rep 2020; 10(1):14041. <u>https://doi.org/10.1038/s41598-020-</u>
17	416	25	
18	417	25	Sandahl TD, Laursen TL, Munk DE, Vilstrup H, Weiss KH, Ott P. The Prevalence of Wilson's
19 20	418		Disease: An Update. Hepatology (Baltimore, Md.) 2020; 71(2):722–32.
20 21	419		https://doi.org/10.1002/hep.30911.
21	420		
23			https://doi.org/10.1002/hep.30911.
24	421		
25			
26	422		
27			
28	100		
29	423		
30 31			
32	424		
33			
34	10.5		
35	425		
36			
37	426		
38			
39	107		
40 41	427		
42			
43	428		
44			
45	420		
46	429		
47			
48	430		
49 50			
50 51	121		
52	431		
53			
54	432		
55			
56	422		
57	433		
58			
59 60			
00			


Fi	gure Legends
Fi	gure 1: Distribution of WD subtypes by gender (a) and age (b)
Fiş	gure 2: Most frequent (Top-10) comorbidities of WD patients


18 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

to been terms only

Page 20 of 26







98x86mm (150 x 150 DPI)

Other joint disorder		50.9%
Other and unspecified soft tissue disorders		
other and anspeaned sort assue disorders		49.3%
Dorsalgia		49.1%
		40.170
Disorders of lipoprotein metabolism and other lipidemias		45.9%
Essential (primary) hypertension		45.2%
Other anxiety disorders		42.00/
		42.9%
Other diseases of liver		40.0%
		1010/0
Gastro-esophageal reflux disease		38.2%
Vitamin D deficiency		33.7%
Quanuaisht and shasity		22.0%
Overweight and obesity		33.0%
0%	10% 20% 30%	40% 50% 60%
Figure 2: Most frequent (Ton-10) comorbid	ities of WD natie	nts
rigure 2. Host hequent (10p 10) contribut	icies of we putte	1105
166x101mm (300 x 300 D	PI)	
	Disorders of lipoprotein metabolism and other lipidemias Essential (primary) hypertension Other anxiety disorders Other diseases of liver Gastro-esophageal reflux disease Vitamin D deficiency Overweight and obesity 0% Figure 2: Most frequent (Top-10) comorbid	Other and unspecified soft tissue disorders Dorsalgia Disorders of lipoprotein metabolism and other lipidemias Essential (primary) hypertension Other anxiety disorders Other diseases of liver Gastro-esophageal reflux disease Vitamin D deficiency Overweight and obesity

Manifestations	Ν	% subtype	% overall cohort (N
Hepatic subtype* (N=1,202)			
Liver signs and symptoms	1,092	90.8%	51.6%
Cirrhosis	456	37.9%	21.6%
Hepatitis	347	28.9%	16.4%
Neurologic subtype* (N=1,206)			
Cognitive defects	611	50.7%	28.9%
Ataxia and gait abnormalities	436	36.2%	20.6%
Dysphagia	328	27.2%	15.5%
Psychiatric subtype* (N=1,003)			
Mood disorders	867	86.4%	41.0%
Mix of symptoms, children	224	22.3%	10.6%
Paranoia and schizophrenia	199	19.8%	9.4%
* These groups are not mutually exclusive.			

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Table 1: Selected baseline characteristics of WD patients, overall and by subtype						
	Hepatic* N=1,202	Neurologic* N=1,206	Psychiatric* N=1,003	Overal N=2,11		
Age at index date (years), mean (SD)	40.4 (19.08)	42.3 (20.70)	39.2 (20.19)	39.9 (20.		
Male, N (%)	607 (50.5%)	659 (54.6%)	558 (55.6%)	1,096 (51.		
US Region of residence at index, N (%)						
Northeast	254 (21.1%)	246 (20.4%)	182 (18.2%)	462 (21.8		
South	376 (31.3%)	398 (33.0%)	332 (33.1%)	647 (30.6		
Midwest	275 (22.9%)	292 (24.2%)	249 (24.8%)	502 (23.7		
West	297 (24.7%)	270 (22.4%)	240 (23.9%)	504 (23.8		
Physician specialty of primary WD diagnosis, N (%)**						
Gastroenterology	197 (16.4%)	117 (9.7%)	90 (9.0%)	279 (13.2		
General / Family Practice	136 (11.3%)	133 (11.0%)	124 (12.4%)	266 (12.6		
Ophthalmology / Optometry	61 (5.1%)	59 (4.9%)	50 (5.0%)	101 (4.8		
Neurology	41 (3.4%)	75 (6.228%)	48 (4.8%)	88 (4.29		
Follow-up period (years), mean (SD)	2.2 (1.28)	2.1 (1.25)	2.1 (1.26)	2.2 (1.2		
Never treated, N (%)	962 (80.0%)	1,044 (86.6%)	881 (87.8%)	1,755 (83.		
* These groups are not mutually exclusive						

* These groups are not mutually exclusive.

** This is the primary physician specialty for the first claim with WD as the primary diagnosis. Due to limitations in the analysis of the prevalent WD population, it cannot be inferred with certainty that it represents the first diagnosis.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

1	
2	
3	
4	
5	
6	
7	
8	
9	
	0
1	1
1	2
1	3
1	4
1	5
1	6
1	7
1	, 8
1	0
1	9
- 2	0
2	1
2	2 3
2	3
2	4
2	5
2	6
2	4 5 6 7 8 9 0
2	/
2	8
2	9
3	0
3	1
3	2
3	_ ז
3	
3	
3	5
3	6
3	/ 8
3	9
	0
4	
	2
4	
-	-
4	
4	-
4	
4	7
4	8
4	9
	0
	1
5	
J	
5	
_	4
5	5
5	6
5	7
	, 8
J	9
	9 0

60

1

Table 1: Crude and age-standardized WD period prevalence 2017–2019

	N	Prevalence per million (95% CI)
Crude prevalence (overall)	1,481	21.2 (20.1-22.3)
Age		
0- <18	256	12.4 (10.9-14.0)
18-<40	490	27.1 (24.7-29.5)
40-<65	581	26.1 (24.0-28.2)
65+	154	17.1 (14.4-19.8)
Sex		
Male	697	21.2 (19.7-22.8)
Female	784	21.1 (19.7-22.6)
Region	-	
Northeast	344	24.1 (21.6-26.7)
South	439	18.4 (16.7-20.1)
Midwest	355	22.2 (19.9-24.5)
West	319	21.6 (19.2-24.0)
Missing	24	
US-adjusted prevalence	1,481	22.0 (20.9-23.1)
WHO-adjusted prevalence	1,481	21.4 (20.4-22.5)

Standardized to the age distribution of the total world population in year 2000-2025, according to WHO *Standardized to the age distribution of the total US population in year 2010, according to Census Bureau

Fang et al. Supplemental Material

Supplementary Table 1. ICD-10 Codes for identification of hepatic subtype

	ICD-10 Code	Description
Elevated serum aminotransferases	R74	Nonspecific elevation of levels of transaminase and lactic acid dehydrogenase [LDH]
Acute hepatitis (not viral)	K72	Acute and subacute hepatic failure
Coagulopathy	D68	Coagulation defect, unspecified
Hepatic	5722	Hepatic encephalopathy
encephalopathy	K727	Hepatic encephalopathy
Cirrhosis	К717	Toxic liver disease with fibrosis and cirrhosis of liver
(decompensated or compensated)	5715	Cirrhosis of liver without mention of alcohol
compensated)	К74	Fibrosis and cirrhosis of liver
	К704	Alcoholic hepatic failure
-	K711	Toxic liver disease with hepatic necrosis
Liver failure	К720	Acute and subacute hepatic failure
-	K721	Chronic hepatic failure
-	К729	Hepatic failure, unspecified
	18501	Esophageal varices with bleeding
	18511	Secondary esophageal varices with bleeding
Variceal hemorrhage	1983	Esophageal varices with bleeding in diseases classified elsewhere
-	4560	Esophageal varices with bleeding
	45620	Esophageal varices in diseases classifies elsewhere, with bleeding
Portal hypertension	K766	Portal hypertension
	5723	Portal hypertension
Hepatocellular carcinoma	C220	Liver cell carcinoma

Supplementary Table 2. ICD-10 Codes for identification of neurological subtype

	ICD-10 Code	Description
	R251	Tremor, unspecified
Tremor	G251	Drug-induced tremor
	G252	Other specified forms of tremor
	G250	Essential tremor

	3331	Essential and other specified forms of tremor
	G20	Parkinson's disease
	G219	Secondary parkinsonism, unspecified
	G218	Other secondary parkinsonism
	G2122	Neuroleptic induced parkinsonism
	G214	Vascular parkinsonism
Parkinsonism or	G2119	Other drug induced secondary parkinsonism
akinetic rigid	3321	Secondary parkinsonism
syndrome	G212	Secondary parkinsonism dur to other external agents
	G213	Postencephalitic parkinsonism
	G8903	Parkinson's disease mg
	G211	Other drug induced secondary parkinsonism
	G22	Parkinsonism in diseases classified elsewhere
	G21	Secondary parkinsonism
	R2689	Other abnormalities of gait and mobility
	R269	Unspecified abnormalities of gait and mobility
Gait abnormalities/ataxia	R26	Abnormalities of gait and mobility
	R268	Other abnormalities of gait and mobility
	R270	Ataxia, unspecified
	78451	Dysarthria
Dysarthria	R471	Dysarthria and anarthria
Dysurtinia	169222	Dysarthria following other nontraumatic intracranial hemorrhage
	169022	Dysarthria following nontraumatic subarachnoid hemorrhage
	G249	Dystonia, unspecified
Dystonia	G248	Other dystonia
	G24	Dystonia
Pseudobulbar palsy	G1220	Motor neuron disease unspecified
i seuuobulbai paisy	33523	Pseudobulbar palsy
	G40	Epilepsy and recurrent seizures
Seizures	F445	Conversion disorder with seizures or convulsions
	R568	Other and unspecified convulsions
Migraine	G43	Migraine
Somatoform autonomic dysfunction	F45	Somatoform disorders

1
2
3
4
5
6
7
8
9
) 10
11
11
12
13
14
15
16
17
13 14 15 16 17 18
19
20
21
20 21 22 23 24 25 26 27 28 29 30
23
24
25
25
20
27 28
28
29
30
31
32
33
34 35
35
36
37
38
39
40
40 41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
50
57
58
59
~ ~

60

	G3184	Mild cognitive impairment, so stated
	F03	Unspecified dementia
Cognitive disorder	F05	Delirium due to known physiological condition
	F06	Other mental disorders due to known physiological condition
	331883	Mild cognitive impairment, so stated

Supplementary Table 3. ICD-10 Codes for identification of psychiatric subtype

	ICD-10 Code	Description
	F32	Major depressive disorder, single episode
Depression	F33	Major depressive disorder, recurrent
	F34	Persistent mood disorder
	F48	Nonpsychotic mental disorder, unspecified
	F40	Phobic anxiety disorder
	F41	Other anxiety disorder
Neuroses	F42	Obsessive compulsive disorder
	F43	Reaction to severe stress and adjustment disorders
	F44	Dissociative and conversion disorders
	F45	Somatoform disorders
	F29	Unspecified psychosis not due to substance or known psychological condition
	F20	Schizophrenia
	F21	Schizotypal disorder
Psychosis	F22	Delusional disorders
1 37010313	F23	Brief psychotic disorder
	F24	Shared psychotic disorder
	F25	Schizoaffective disorder
	F28	Other psychotic disorder not due to a substance or known physiological condition
	F07	Personality change due to known physiological condition
Personality changes	F60	Specific personality disorder
r croonancy changes	F61	Mixed and other personality disorder
	F62	Enduring personality change
Bipolar disorder	F31	Bipolar affective disorder

Wilson Disease in the US - Epidemiology and Real-World Patient Characteristics Based on a Retrospective Observational Health Claims Study

Journal:	BMJ Open
Manuscript ID	bmjopen-2024-089032.R1
Article Type:	Original research
Date Submitted by the Author:	14-Oct-2024
Complete List of Authors:	Fang, Shona; Alexion Pharmaceuticals Inc Strader, Carey; Oracle America Inc Costantino, Halley; Oracle America Inc Weiss, Karl Heinz; Salem Hospital Hedera, Peter; University of Louisville
Primary Subject Heading :	Epidemiology
Secondary Subject Heading:	Public health, Gastroenterology and hepatology, General practice / Family practice, Neurology
Keywords:	Prevalence, EPIDEMIOLOGY, Cross-Sectional Studies, Chronic Disease





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

terez oni

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies



Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

1	Wilson Disease in the US - Epidemiology and Real-World Patient
2	Characteristics Based on a Retrospective Observational Health
3	Claims Study
4	
5	Shona Fang, ScD ¹ Carey Strader, ² Halley Costantino, ² Karl Heinz Weiss, MD ³ Peter Hedera, MD,
6	PhD ⁴
7	¹ Alexion Pharmaceuticals Inc, Boston, MA; ² Oracle America Inc, Redwood Shores, CA; ³ Salem
8	Hospital, Heidelberg, Germany; ⁴ University of Louisville, Louisville, KY
9	ORCID: Peter Hedera 0000-0003-2699-4085, Halley Costantino 0009-0000-6658-6057
10	Corresponding author:
11	Shona Fang, ScD
12	121 Seaport Avenue
13	Boston, MA 02210
14	shona.fang@alexion.com
15	Word count: 3,648
16	Running title: Epidemiology of Wilson Disease in the US
17	Financial Disclosure/Conflict of Interest concerning the research related to the manuscript: CS and
18	HC declare being employees of Oracle America, which received funding from Alexion
19	Pharmaceuticals to conduct this study. PH has no financial relationships to disclose. KHW declares no
20	conflicts of interest that pertains to this work. SF is an employee of Alexion, AstraZeneca Rare
21	Disease and owns stock in AstraZeneca.

22 Funding Sources for study: This study was funded by Alexion Pharmaceuticals.

59 60 BMJ Open

2 3	23	Abstract
4 5		
5 6 7	24	Objectives: To describe the epidemiology, patient characteristics and comorbidities in patients with
8 9	25	Wilson disease (WD) in the US.
10 11 12	26	Design: Retrospective, population-based study
13 14	27	Setting: The study used the US Komodo claims database containing records regarding medical claims
15 16 17	28	for over 120 million individuals.
18 19	29	Participants: Patients with WD were identified via ICD10 code during the study period 2016–2019. A
20 21 22	30	further stratification by disease subtype ("hepatic", "neurologic" and "psychiatric") was performed.
23 24	31	Main outcome measures: WD prevalence was reported by age, sex, and US census regions/divisions.
25 26	32	Adjusted prevalence was calculated using age-specific prevalence standardized to the US (2010 US
27 28	33	census) and to the world (WHO 2000–2025) to enable comparisons across countries, using direct
29 30 31	34	standardization of prevalence estimates by age group.
32 33	35	<i>Results:</i> Overall, 2,115 WD patients were identified during the study period. Among them, 56.8% had
34 35	36	hepatic symptoms, 57.0% neurologic symptoms and 47.4% psychiatric symptoms. The most frequent
36 37 38	37	manifestations in hepatic patients were liver signs and symptoms (90.8%), in neurologic patients
39	38	cognitive defects (50.7%), and in psychiatric patients mood disorders (86.4%). The mean age in the
40 41 42	39	overall cohort was 39.9 years. Prevalence estimation was based on 1,481 WD patients between 2017
42 43 44	40	and 2019. The 2017–2019 crude period prevalence was 21.2 patients per million (95% confidence
45 46	41	interval: 20.1–22.3), with similar prevalence observed for both sexes.
47 48	42	Conclusions: This study provides important real-world data on the diagnosed prevalence of WD in the
49 50 51	43	US and revealed the comorbidities associated with various disease subtypes, thereby providing a
52 53	44	comprehensive basis for guiding physicians and policy makers in the management of this chronic
54 55 56 57 58 59	45	disease.

1 2 3 4	46	Strengths and limitations of this study
5 6	47	• This study estimated the diagnosed prevalence of WD for the first time in the US, by using a
7 8	48	large, nationally representative claims database . The real-world nature of the data helps
9 10 11	49	estimate the observed frequency of Wilson disease in the US using ICD-10 codes specific to
11 12 13	50	WD.
14 15	51	• The classification of patients into subtypes, and especially the novel approach to differentiate
16 17	52	psychiatric symptoms from neurological symptoms, was a further strength of this study.
18 19	53	• Besides general limitations inherent to claims data, the limitations specific to this study
20 21	54	included a limited study period after the introduction of a new WD-specific ICD-10 code in
22 23	55	2015.
24 25 26	56	• The used claims data did not capture information on OTC medications and the treated patients
20 27 28	57	represented the proportion of patients with prescription treatment only.
28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 50 51 52 53 54 55 56 57 58 59 60	58	

Confidential - Oracle Restricter peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open

59	Introduction
39	Introduction

Wilson disease (WD) is an autosomal recessive condition which leads to an excessive copper deposition in body organs, particularly in the liver and the central nervous system.¹ This genetic disorder is caused by mutations of the P-type ATPase copper transporter ATP7B gene located in the human chromosome 13.2 To date, more than 600 variants in the ATP7B gene have been described, and most WD patients are compound heterozygous with two different ATP7B variants, complicating and prolonging genetic WD diagnosis.³ WD generally presents in childhood and young adulthood with the most common age of presentation between 10 and 20 years, though patients can occasionally present before the age of 5 years and after the age of 70 years.⁴

Clinical presentation of WD includes a combination of hepatic, neurologic, psychiatric, and ophthalmologic symptoms. Psychiatric symptoms often precede the diagnosis of WD and include personality changes, depression, cognitive changes, and anxiety.⁵ The neurologic symptoms of WD mostly refer to dysfunction in the extrapyramidal system including dysarthria, dystonia, gait abnormalities, tremor, parkinsonism, chorea, and seizures.⁶ Psychiatric symptoms have been only recently recognized as independent manifestations of WD, as it was previously assumed that they occur together with neurological symptoms, and patients were often referred to as having neuro-psychiatric disorders.⁷ The symptoms related to hepatic dysfunction in WD can range from an asymptomatic increase in liver enzyme levels to severe liver failure. Typically, early on in disease progression there is a mild increase in transaminases, which then may progress to chronic active hepatitis, followed by fibrosis and cirrhosis.⁸

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

WD is a rare disease with recent worldwide clinical prevalence estimates ranging from approximately 16.7 to 25 patients per million,⁹ although the prevalence can vary across countries and may be higher in selected regions such as in some Asian communities.¹⁰ Interestingly, there is a discrepancy of WD prevalence estimates originating from epidemiological compared to genetic studies and recent genetic data with a considerably higher prevalence (139 per million) indicate that the prevalence of WD may be underestimated.¹¹ The possibility of underdiagnosis, misdiagnosis and the lack of accounting for incomplete variant penetrance in the genetic calculations were hypothesized as the main reasons for

BMJ Open

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

the observed inconsistency between genetic vs. clinical data.^{11,12} For the US, population-based
epidemiological data are still scarce. A previous study reported a genetic birth prevalence of 18.2 per
million births,¹³ and an abstract on cardiac manifestations in WD reported a prevalence of 26 patients
per million, but no details of methodology.¹⁴

Thus, large population-based studies assessing the epidemiology of WD and its subtypes in the US are needed, allowing for a greater characterization around the spectrum of disease severity and the diagnosed prevalence of WD. Here we present the US-specific data from a recently completed multicountry real-world evidence study that used claims data to investigate various aspects of WD in a reallife setting including epidemiology and patient demographic and clinical characteristics.

95 Methods

96 Study design

This retrospective, population-based observational study used health insurance claims data to assess WD epidemiology and patient characteristics using the US Komodo Health claims database available from 2012–2020.¹⁵ Komodo's private payor-complete database contains records regarding prescription and/or medical claims for over 120 million individuals, collected from more than 150 private insurers in the US, including Medicaid managed-care and Medicare Advantage plans. This study used the closed claims available in the database. Closed claims come directly from the payer and provide the complete patient journey, such as full medical and/or prescription benefit information including insurance eligibility.

105 Population

Patients were selected based on their first reported WD diagnosis (index event) in the claims database
between 2016 and 2019 (study period). The diagnosis was based on code (ICD-10 code E83.01 or
ICD-9-CM code 275.1 prior to October 1, 2015). The standard ICD-9 diagnostic code for WD could
also include another rare condition called Menkes disease. The WD-specific ICD-10 code (E83.01)
was introduced in the US on October 1, 2015. A WD diagnosis was defined as at least one inpatient or
two outpatient visits with a WD ICD-10 code, separated by at least 30 days during the study period.

BMJ Open

No age restriction was imposed. Patients were excluded from the study if they had at least one
prescription for a copper replacement drug during the study period. This was applied to rule out
patients with Menkes disease which is treated by copper replacement drugs.
Cohorts and subgroups
The cohort presented here includes patients that fulfilled the criteria for at least one WD diagnosis at
any time during the study period (2016–2019) and a continuous enrollment for at least one calendar
year before the index event. Separately, prevalence was assessed in the period between 2017 and 2019
for patients that had a history of at least one WD diagnosis at any time during that period and a
continuous enrollment for at least two calendar years. This separate assessment period for prevalence
estimation was based on the WD-specific diagnosis code becoming effective in the US only in 2015.
Due to the possibility of miscoding, the most accurate prevalence estimation of WD can be made
between 2017 and 2019, as this period includes at least one full calendar year since the introduction of
the new code.
A further stratification by WD subtypes was performed. The subtypes "hepatic", "neurologic" and
"psychiatric" were not mutually exclusive or strictly delineated but were based on the presence of
signs and symptoms. Patients were assigned to the hepatic subtype if they were diagnosed with liver
signs and symptoms, acute hepatitis (not viral), cirrhosis (decompensated or compensated), liver
failure, portal hypertension, or hepatocellular carcinoma. Patients assigned to the neurologic subtype
had a diagnosis for tremor, parkinsonism or akinetic rigid syndrome, gait abnormalities/ataxia,
dysarthria, dystonia, chorea, dysphagia, myopathy, seizures, migraine, somatoform autonomic
dysfunction or cognitive disorder. Patients diagnosed with mood disorders, paranoia/schizophrenia,
psychosis, or personality disorders were assigned to the psychiatric subtype. WD manifestations were
defined as the occurrence of specific signs or symptoms associated with each of the subtypes and were
identified using respective ICD-10 codes (see Supplementary Tables 1–3).

Variables

Data on patient characteristics (age, sex, region of residence), physician specialty, proportion of patients never treated, distribution of subtypes and manifestations were ascertained at baseline.

BMJ Open

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Comorbidities were assessed during the study period (2016-2019). Overall, age-, sex-, and region-specific prevalence (crude and age-adjusted period prevalence) were assessed in the period between 2017 and 2019. A rationale for considering a period prevalence rather than an annual prevalence was that the identification of WD patients was based on ICD-10 codes, without considering WD treatment or laboratory records, and the assumption that WD patients who are well managed using over the counter (OTC) or prescription medication may not necessarily visit a health care provider (HCP) each year. A further reason for using a period prevalence was to account for possible misdiagnosis in the first year after the introduction of the ICD-10 code for WD.

Data analysis

Descriptive statistics were calculated for demographic and baseline characteristics (overall and by subtype). Means and standard deviations (SDs) were provided for continuous or discrete data. Frequencies and percentages were provided for categorical data. For WD manifestations, the frequencies of occurrence of specific ICD-10 codes within subtypes and within the overall patient cohort were calculated and the three most frequent manifestations were listed by subtype. For comorbidities, all recorded diagnoses (ICD-10 codes level-3) at any time during the study period were ranked according to frequency and a list of the 10 most frequent comorbidities in the overall cohort were reported. In addition, the Charlson Comorbidity index (CCI; version of 2011), an assessment tool designed to predict mortality in patients with multiple comorbidities,¹⁶ was assessed for each patient and a mean score including SD (higher scores indicating greater mortality risk and more severe comorbid conditions) was calculated for the overall cohort. Crude period prevalence was calculated from the number of WD cases identified and was expressed as patients per million including 95% confidence intervals (CI). The denominator was the number of patients with continuous enrollment spanning the period of interest (2017–2019) and the numerator was any patient from the denominator with at least one WD diagnosis claim during the period of interest. Prevalence was reported by age, sex, and US census regions/divisions. Adjusted prevalence was calculated using age-specific prevalence standardized to the US (2010 US census) and to the world (WHO 2000-2025) to enable comparisons across countries, using direct standardization of prevalence estimates by age group.

This was a multinational study which was approved by an institutional review board (IRB) and/or

independent ethics committee (IEC) in each participating country. The IRB for the US was Pearl

Pathways. The study was conducted in accordance with legal and regulatory requirements, as well as

with scientific purpose, value and rigor, and followed generally accepted research practices described

The data that support the findings of this study are available from Komodo Health. Restrictions apply

to the availability of these data, which were used under license for this study. Access to data must be

in Good Pharmacoepidemiology Practices guidelines issued by the International Society for

Pharmacoepidemiology. The Institutional board and approval were: Pearl Pathways IRB and

Patients or the public were not actively involved in this observational study.

2 3	166
4 5 6	167
7 8	168
9 10	169
11 12	170
13 14	171
15 16 17	172
18 19	173
20 21	174
22 23	175
24 25 26	176
26 27 28	176
20 29 30	177
31 32	178
33 34	179
35 36	180
37 38	181
39 40 41	182
42 43	183
44 45	184
46 47	185
48 49	186
50 51 52	187
52 53 54	188
55 56	189
57 58	190
59 60	191

166 Ethics statement

Approval number is #20-KANT-224

Patient and public involvement

Data availability statement

requested through Oracle.

Results
WD subtypes and manifestations
The observed cohort included 2,115 WD patients identified between 2016 and 2019. Among these,
more than half had hepatic and/or neurologic symptoms (56.8% and 57.0%, respectively) and around
half had psychiatric symptoms (47.4%). Most patients had overlapping subtypes, presenting
concomitantly with hepatic, neurologic, and/or psychiatric symptoms, presenting concomitantly with
hepatic, neurologic, and/or psychiatric signs and symptoms (see Supplementary Figure 1). For
instance, 734 (34.7%) had 2 overlapping conditions of hepatic, neurologic, and/or psychiatric and 422
(20.0%) WD patients presented with concomitant hepatic, neurological, and psychiatric conditions.
Figure 1 illustrates the distribution of sex (a) and age (b) within subtypes. Slightly more male than
female patients had neurologic (54.6%) and psychiatric (55.6%) symptoms, whereas the sex
distribution was equal in the hepatic subtype. With regards to age distribution, most patients in all
subtypes were in the age groups between 18 to 39 years and 40 to 64 years. The distribution of young 8

BMJ Open

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

(0–17 years) and older (above 65 years) patients was also similar between subtypes, though there were slightly more older patients in the neurologic subtype (21% vs. 16% [hepatic] and 17% [psychiatric]). The most frequent manifestations associated with the different subtypes and their proportion in the overall cohort are highlighted in Table 1. Hepatic patients most frequently experienced liver signs and symptoms (90.8%), cirrhosis (37.9%) and hepatitis (28.9%). Neurologic patients most frequently experienced cognitive defects (50.7%), ataxia and gait abnormalities (36.2%) and dysphagia (27.2%). Psychiatric patients most frequently experienced mood disorders (86.4%), a mix of symptoms in children (22.3%) and paranoia/schizophrenia (19.8%). **Baseline characteristics** Selected baseline characteristics of the overall cohort and by subtype are displayed in Table 2. The mean age in the overall cohort was 39.9 years (SD=20.1 years). The lowest mean age was reported for the psychiatric subtype (39.2 years, SD=20.2 years) and the highest for the neurologic subtype (42.3 years, SD=20.7 years). Overall, 51.8% were male patients. A larger portion of patients came from the South (30.6%) and fewer from the Northeast (21.8%) with little difference between subtypes. While for a majority (54.2%) of overall WD cases no information was available regarding the specialists

208 managing the primary WD diagnosis, the available results showed that patients were mostly in the care

209 of gastroenterologists (13.2%) and general/family practitioners (12.6%). Hepatic patients were more

210 frequently seen by gastroenterologists (16.4%), as compared to the other subtypes (9.7% of neurologic

211 patients and 9.0% of psychiatric patients). On average, patients were followed up for 2.2 years

(SD=1.3 years) with little difference between subtypes. Among all patients, the majority (83.0%) were
 never treated with a reimbursable WD prescription medication during the study period.

214 Comorbidities

WD patients were diagnosed with a broad spectrum of comorbidities. The most common clinical
conditions diagnosed during the study period included other joint disorders (50.9%), unspecified soft
tissue disorders (49.3%), dorsalgia (49.1%), disorders of lipoprotein metabolism and other lipidemias
(45.9%), essential hypertension (45.2%), anxiety disorders (42.9%), and other diseases of liver

BMJ Open

(40.0%), Figure 2. The extent of comorbidities was also reflected by a mean CCI score of 1.92
(SD=2.68).

221 Prevalence

Prevalence estimation was based on 1,481 WD patients between 2017 and 2019. The 2017–2019 crude period prevalence was 21.2 patients per million (95% CI: 20.1–22.3), with similar prevalence observed for both sexes (male: 21.2 per million, 95% CI: 19.7-22.8 and female: 21.1 per million, 95% CI: 19.7–22.6), Table 3. The crude period prevalence peaked among young adults in the 18 to 39 years age group (27.1 per million, 95% CI: 24.7–29.5), followed closely by adults 40 to 64 years old (26.1 per million, 95% CI: 24.0–28.2). The highest crude period prevalence was recorded in the Northeast (24.1 per million, 95% CI: 21.6–26.7), followed by the Midwestern (22.2 per million, 95% CI: 19.9–24.5), Western (21.6 per million, 95% CI: 19.2–24.0), and Southern (18.4 per million, 95% CI: 16.7–20.1) regions of the US.

Adjusted period prevalence was calculated using age-specific prevalence standardized to the US (2010 US census) and to the world (WHO 2000-2025). Between 2017 and 2019, both the US-adjusted and WHO-adjusted period prevalences were similar (22.0 per million, 95% CI: 20.9–23.1 and 21.4 per million, 95% CI: 20.4–22.5, respectively) to the crude period prevalence observed in this study.

³⁹ 235 **Discussion**

4142 236 Principal findings and implications

There is a gap of knowledge regarding the epidemiology and clinical characteristics of WD patients
from a national and international perspective. In this large population-based study we assessed WD
patient characteristics and epidemiology in the US.

- 51 240 Approximately two-thirds of the cohort showed hepatic and/or neurologic symptoms, which is
- 53 241 consistent with the natural disease course, as WD mostly affects the liver and brain.¹⁷ Typically,

hepatic symptoms precede the onset of neurologic symptoms and may thus be diagnosed at a younger hepatic symptom precede the onset of neurologic symptoms and may thus be diagnosed at a younger

 $\frac{57}{58}$ 243 age². In line with this, though not as evident in the age distribution by subtypes, the mean age at index

in the hepatic subtype was slightly lower compared to the neurologic subtype. In agreement with our

BMJ Open

data on sex distribution in the neurologic and psychiatric subtypes, a registry-based study observed

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

that the neuropsychiatric WD form occurred more frequently in men (67%) vs. women (49%).¹⁸ Our results also revealed the extent of comorbidities associated with various disease subtypes, as some of the most frequently reported manifestations were quite severe (e.g., around 40% of patients in the hepatic subtype presented with cirrhosis). The frequency of hepatic, neurologic, and psychiatric presentations, as well as the manifestations within these subtypes varies considerably in other published studies.⁴ Considering the great variability in WD symptoms, it is likely that there is referral bias. A review of several independent case series suggested that dysarthria, gait abnormality/ataxia and dystonia are the most frequent manifestations in the neurologic subtype, which partially reflects our findings.⁴ The higher rates of dystonia and dysarthria reported in the literature may be explained by the fact that only symptomatic conditions that require treatment get captured in the claims under the ICD-10 diagnosis code. Furthermore, a study from China reported distributions of hepatic manifestations (e.g., 22% cirrhosis and 11% cirrhotic complications) which were similar to our findings.¹⁹ WD patients in our study were in the typical age range for first symptom onset and disease progression (between the second and sixth decade of life). We found a slightly lower mean age in the psychiatric subtype compared to the other subtypes, which might reflect that psychiatric manifestations are often the first symptoms.⁷ The earlier diagnosis of psychiatric WD may highlight a critical gap in care for these patients, as neurologic and psychiatric involvements have been previously assessed in tandem, with neurologic symptoms becoming more apparent later in life. Given the recessive nature of WD, the results confirmed the expectation of a relatively even distribution of cases across sexes, which also aligns with previous studies conducted in France,²⁰ and Hong Kong.¹⁹ The geographical distribution within the US, with a larger portion of patients coming from the South and fewer from the Northeast, might correspond to the distribution of major university centres in the US where WD patients are typically diagnosed. Given the nature of the disease, it is not surprising that patients were primarily in the care of gastroenterologists (most pronounced in hepatic patients), though a considerable fraction of patients was also diagnosed or treated by general or family practitioners who might be the first contact points. The high rate of patients never treated with a reimbursable WD medication during the study

BMJ Open

period was likely due to the use of OTC zinc preparations which are not covered by insurers in the US, the refusal to take medications and rely solely on a low-copper diet, or the hypothesis that some physicians used the WD diagnosis code to initiate further testing for the patients but did not prescribe a WD medication at that initial stage. Further investigation on this aspect is warranted given the chronic nature of this disease. Furthermore, our results demonstrated that WD patients were diagnosed with a broad spectrum of comorbidities, most frequently affecting joints, soft tissues, and the cardiovascular system, as well as pain symptoms and metabolic disorders. Comorbidities of WD are rarely described in the literature and vary considerably, however, our findings are at least partially consistent with comorbidities reported in the literature. Kruger et al and Dziezyc et al described that the most common complications in WD patients were pain, renal, neurologic, cardiac, skin, osteoarticular, or endocrinologic complications and included other organ disturbances. ^{21,22} Only a few population-based studies assessing WD epidemiology have been performed to date world-wide. It is challenging to compare the results from this study to other reports, because of the heterogeneity of the disease and of the heterogeneity in population, diagnosis, and methodologies employed in other studies assessing WD epidemiology. However, the observed prevalence estimates (US-adjusted prevalence: 22.0 patients per million) align well within the WD prevalence range reported in other claims-based studies in France (15 per million), ²³ and China (17.9 per million), ¹⁹ while estimates from a claims-based study in South Korea were slightly higher (38.7 per million).²⁴ Two recent systematic literature reviews assessed WD prevalence data originating from populationbased epidemiological as well as genetic studies.^{11,25} Sandahl et al. reported a crude population-based prevalence between 25 and 34.5 per million,²⁵ and underlined that specific populations in Croatia, Sardinia, Israel, Costa Rica, Middle Eastern countries, Pakistan and India had considerably higher prevalence estimates, either related to consanguinity or higher mutation frequencies. Gao et al. performed a meta-analysis resulting in a pooled population-based prevalence of 14 patients per million.¹¹ Both reviews mentioned that at least in some studies a higher genetic vs. clinically based prevalence could be observed. Gao et al. reported a pooled prevalence at birth of 127 per million.¹¹

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Overall, it seems evident that many factors such as the still uncertain mutational spectrum and penetrance of WD variants, the unclear effect of combined mutations and epigenetic factors, methodological differences in studies, underdiagnosis, changes in diagnostic awareness and treatment options over time, as well as geographic factors may influence WD prevalence estimates. Thus, it is important to assess epidemiological data from large, population-based studies, as the one presented here.

305 Strengths and limitations

This study benefitted from several strengths. Data elements extracted from claims, some of which are not generally available in literature or patient registries, are collected routinely in clinical practice and represent real-world activities and outcomes. The real-world nature of the data helps estimate the observed frequency of diagnosed diseases using ICD-10 codes. The ICD-10 codes for WD are highly specific, despite any limitations in coding or misdiagnosis which may occur. The Komodo claims data are large and nationally representative based on comparisons made to the US census estimates (by age, sex, and region). The closed claims provide a longitudinal history that facilitates the analysis of the natural history of the disease, healthcare utilization, and treatment dynamics. Of note, the crude prevalence observed in this study between 2017 and 2019 was comparable to the US age-standardized adjusted results, reaffirming the representativeness of the Komodo data for rare disease research in the US. The classification of patients into subtypes, and especially the novel approach to differentiate psychiatric symptoms from neurological symptoms, was a further strength of this study. There are some general limitations inherent to claims data, such as the potential for errors in diagnosis

There are some general limitations inherent to claims data, such as the potential for errors in diagnosis coding or record keeping at the point of the HCP. Since claims data are used for billing purposes, they only include records for the insured population, therefore projections of the US population assume similarities between the insured and uninsured patients. Leveraging secondary data requires an algorithm for case identification and validated algorithms specific to WD do not currently exist. Claims data contain only reimbursed medical services and thus e.g., results of lab tests or patientreported outcomes are not captured.

BMJ Open

In addition, there were some limitations specific to this study. Epidemiological trends over time were hard to assess given the limited study period and the introduction of the new WD-specific ICD-10 code. Only symptomatic conditions were captured under the ICD-10 code; therefore, no inferences can be made regarding pre-symptomatic patients with WD. The claims data did not capture information on laboratory testing well, and results are not available in claims data. Further the claims data did not capture OTC medications and thus the treated patients represented the proportion of patients with prescription treatment only. The proportion of patients without a claim for a WD-specific treatment was quite high and unexpected however and whether this truly reflects a large proportion of patients on OTC zinc is unclear. Further investigation is needed as to the proportion of WD patients receiving treatment in the US.

335 Conclusions

This claims study provides important real-world data on the prevalence of WD in the US and revealed the extent of comorbidities associated with various disease subtypes. The results of this study extend existing research findings and provide a comprehensive epidemiological basis for guiding physicians and policy makers in the management of this chronic disease. Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

BMJ Open

1		
2 3 4	341	Declarations
5 6 7	342	Acknowledgments
7 8 9	343	Medical writing was provided by Dr. Sophia von Stockum of ZEG – Berlin Center for Epidemiology
10 11 12	344	and Health Research GmbH with editorial input from all authors.
12 13 14	345	Authors' Contributions
15 16	346	SF, CS, KHW and PH were responsible for the design, writing and editing of the final version of the
17 18	347	manuscript. SF, CS and HC were responsible for the execution of the study and HC was responsible
19 20	348	for the analysis of the data. SF is the guarantor. All authors had critically reviewed the manuscript and
21 22 23	349	approved its final version.
24 25	350	Financial Disclosures of all authors (for the preceding 12 months)
26 27	351	PH has no financial relationships to disclose. KHW advises for Alexion, Univar, Orphalan, Desitin,
28 29	352	Tilomed, Ultragenyx, Pfizer, Vivet therapeutics, Abbvie. HC is an employee of Oracle America,
30 31 32	353	which has provided consultancy for Alexion Pharmaceuticals.
33 34	354	Financial Disclosures
35 36 37	355	PH has no financial relationships to disclose. KHW declares no conflicts of interest that pertains to
38 39	356	this work. SF is an employee of Alexion, AstraZeneca Rare Disease and may own stock in
40 41	357	AstraZeneca.
42 43 44	358	AstraZeneca.
45 46 47	359	
48 49 50	360	
51 52 53	361	
54 55	362	
56 57 58 59 60	363	

1 ว			
2 3			
4	364	R	eferences
5	365	1	Moini M, To U, Schilsky ML. Recent advances in Wilson disease. Transl Gastroenterol Hepatol
6 7	366	1	2021; 6:21. <u>https://doi.org/10.21037/tgh-2020-02</u> .
8	367	2	Kasztelan-Szczerbinska B, Cichoz-Lach H. Wilson's Disease: An Update on the Diagnostic
9	368	_	Workup and Management. J Clin Med 2021; 10(21). <u>https://doi.org/10.3390/jcm10215097</u> .
10	369	3	Ferenci P. Regional distribution of mutations of the ATP7B gene in patients with Wilson disease:
11	370		impact on genetic testing. Hum Genet 2006; 120(2):151–59. https://doi.org/10.1007/s00439-006-
12	371		0202-5.
13 14	372	4	Mulligan C, Bronstein JM. Wilson Disease: An Overview and Approach to Management. Neurol
15	373		Clin 2020; 38(2):417–32. https://doi.org/10.1016/j.ncl.2020.01.005.
16	374	5	Akil M, Schwartz JA, Dutchak D, Yuzbasiyan-Gurkan V, Brewer GJ. The psychiatric
17	375		presentations of Wilson's disease. J Neuropsychiatry Clin Neurosci 1991; 3(4):377-82.
18	376		https://doi.org/10.1176/jnp.3.4.377.
19 20	377	6	WILSON SAK. PROGRESSIVE LENTICULAR DEGENERATION: A FAMILIAL NERVOUS
20 21	378		DISEASE ASSOCIATED WITH CIRRHOSIS OF THE LIVER. Brain 1912; 34(4):295–507.
22	379		https://doi.org/10.1093/brain/34.4.295.
23	380	7	Zimbrean PC, Schilsky ML. Psychiatric aspects of Wilson disease: a review. Gen Hosp Psychiatry
24	381		2014; 36(1):53-62. https://doi.org/10.1016/j.genhosppsych.2013.08.007.
25	382	8	Boga S, Ala A, Schilsky ML. Hepatic features of Wilson disease. Handb Clin Neurol 2017;
26	383		142:91–99. https://doi.org/10.1016/B978-0-444-63625-6.00009-4.
27 28	384	9	Sandahl TD, Ott P. Epidemiology of Wilson Disease. In: Weiss K-H, Schilsky ML. Eds. Wilson
20 29	385		disease. Pathogenesis, molecular mechanisms, diagnosis, treatment and monitoring. Amsterdam:
30	386		Academic Press, 2018; p85–94.
31	387	10	Yamaguchi H, Nagase H, Tokumoto S, et al. Prevalence of Wilson disease based on genome
32	388		databases in Japan. Pediatrics international : official journal of the Japan Pediatric Society 2021;
33	389		63(8):918–22. <u>https://doi.org/10.1111/ped.14565</u> .
34 35	390	11	Gao J, Brackley S, Mann JP. The global prevalence of Wilson disease from next-generation
36	391	10	sequencing data. Genet Med 2019; 21(5):1155–63. https://doi.org/10.1038/s41436-018-0309-9.
37	392	12	Coffey AJ, Durkie M, Hague S, et al. A genetic study of Wilson's disease in the United Kingdom.
38	393	12	Brain 2013; 136(Pt 5):1476–87. https://doi.org/10.1093/brain/awt035.
39	394	13	Olivarez L, Caggana M, Pass KA, Ferguson P, Brewer GJ. Estimate of the frequency of Wilson's
40	395 396		disease in the US Caucasian population: a mutation analysis approach. Annals of human genetics 2001; 65(5):459–63. <u>https://doi.org/10.1046/j.1469-1809.2001.6550459.x</u> .
41 42	390 397	14	Li XJ, Tunio NA, Rana MN, Al-Kindi S, Mansoor E, Sclair S. S1095 Prevalence of Cardiac
43	398	14	Diseases in Wilson's Disease: A National, Population-Based Study. Am J Gastroenterol 2020;
44	399		115(1):S553-S553. https://doi.org/10.14309/01.ajg.0000706428.74725.f8.
45	400	15	Komodo Health. https://www.komodohealth.com/ (accessed Sep 13, 2023).
46	401		Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and
47 40	402	10	score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J
48 49	403		Epidemiol 2011; 173(6):676–82. https://doi.org/10.1093/aje/kwq433.
50	404	17	Członkowska A, Schilsky ML, eds. Handbook of Clinical Neurology : Wilson Disease. Elsevier,
51	405	1,	2017.
52	406	18	Litwin T, Gromadzka G, Członkowska A. Gender differences in Wilson's disease. Journal of the
53	407		Neurological Sciences 2012; 312(1-2):31–35. <u>https://doi.org/10.1016/j.jns.2011.08.028</u> .
54 55	408	19	Cheung K-S, Seto W-K, Fung J, Mak L-Y, Lai C-L, Yuen M-F. Epidemiology and natural history
55 56	409		of Wilson's disease in the Chinese: A territory-based study in Hong Kong between 2000 and 2016.
50 57	410		World J Gastroenterol 2017; 23(43):7716–26. <u>https://doi.org/10.3748/wjg.v23.i43.7716</u> .
58	411	20	Poujois A, Woimant F. Wilson's disease: A 2017 update. Clinics and research in hepatology and
59	412		gastroenterology 2018; 42(6):512–20. https://doi.org/10.1016/j.clinre.2018.03.007.
60			

2			
3	413	21	Kruger E, Nedzesky J, Thomas NA, Cataldo J. PRO72 Common and Serious Comorbidities
4	414		Among Adults with Wilson Disease. Value in Health 2021; 24:S211.
5 6	415		https://doi.org/10.1016/j.jval.2021.04.1057.
6	416	22	Dzieżyc K, Litwin T, Członkowska A. Other organ involvement and clinical aspects of Wilson
7	417	22	disease. Handb Clin Neurol 2017; 142:157–69. https://doi.org/10.1016/B978-0-444-63625-
8	417		
9		22	<u>6.00013-6</u> .
10	419	23	Poujois A, Woimant F, Samson S, Chaine P, Girardot-Tinant N, Tuppin P. Characteristics and
11 12	420		prevalence of Wilson's disease: A 2013 observational population-based study in France. Clinics
13	421		and research in hepatology and gastroenterology 2018; 42(1):57–63.
14	422		https://doi.org/10.1016/j.clinre.2017.05.011.
15	423	24	Choe EJ, Choi JW, Kang M, et al. A population-based epidemiology of Wilson's disease in South
16	424		Korea between 2010 and 2016. Sci Rep 2020; 10(1):14041. https://doi.org/10.1038/s41598-020-
17	425		<u>70976-1</u> .
18	426	25	Sandahl TD, Laursen TL, Munk DE, Vilstrup H, Weiss KH, Ott P. The Prevalence of Wilson's
19	427		Disease: An Update. Hepatology (Baltimore, Md.) 2020; 71(2):722-32.
20	428		https://doi.org/10.1002/hep.30911.
21	420		
22	429		https://doi.org/10.1002/hep.30911.
23 24	430		
24 25			
26	421		
27	431		
28			
29	432		
30			
31	122		
32	433		
33			
34	434		
35			
36 37			
38	435		
39			
40	436		
41			
42			
43	437		
44			
45	438		
46 47			
47 48			
40 49	439		
50			
51	440		
52	110		
53			
54	441		
55			
56	442		
57	-1-1 -2		
58 59			
59 60	443		
00			

Tables 444

1 2 3

4 5

445 Table 1: Most frequent (Top-3) WD manifestations by subtype

5 6	445				
7 8 9		Manifestations	N	% subtype	% overall cohort (N=2,115)
10 11		Hepatic subtype* (N=1,202)			
12 13 14		Liver signs and symptoms	1,092	90.8%	51.6%
15 16		Cirrhosis	456	37.9%	21.6%
17 18 19		Hepatitis	347	28.9%	16.4%
20 21		Neurologic subtype* (N=1,206)			
22 23 24		Cognitive defects	611	50.7%	28.9%
25 26		Ataxia and gait abnormalities	436	36.2%	20.6%
27 28 29		Dysphagia	328	27.2%	15.5%
30 31		Psychiatric subtype* (N=1,003)			
32 33 34		Mood disorders	867	86.4%	41.0%
35 36		Mix of symptoms, children	224	22.3%	10.6%
37 38 39		Paranoia and schizophrenia	199	19.8%	9.4%
40 41	446	* These groups are not mutually exclusive.			
42 43 44	447				
45 46 47					
48 49					
50 51 52					
53 54					
55 56 57					
58 59					

453

448					
449	Table 2: Selected baseline characteristics of	WD patients, overal	l and by subtype		
		Hepatic* N=1,202	Neurologic* N=1,206	Psychiatric* N=1,003	Overall N=2,115
	Age at index date (years), mean (SD)	40.4 (19.08)	42.3 (20.70)	39.2 (20.19)	39.9 (20.06)
	Male, N (%)	607 (50.5%)	659 (54.6%)	558 (55.6%)	1,096 (51.8%
	US Region of residence at index, N (%)				
	Northeast	254 (21.1%)	246 (20.4%)	182 (18.2%)	462 (21.8%)
	South	376 (31.3%)	398 (33.0%)	332 (33.1%)	647 (30.6%)
	Midwest	275 (22.9%)	292 (24.2%)	249 (24.8%)	502 (23.7%)
	West	297 (24.7%)	270 (22.4%)	240 (23.9%)	504 (23.8%)
	Physician specialty of primary WD diagnosis, N (%)**	2			
	Gastroenterology	197 (16.4%)	117 (9.7%)	90 (9.0%)	279 (13.2%)
	General / Family Practice	136 (11.3%)	133 (11.0%)	124 (12.4%)	266 (12.6%)
	Ophthalmology / Optometry	61 (5.1%)	59 (4.9%)	50 (5.0%)	101 (4.8%)
	Neurology	41 (3.4%)	75 (6.228%)	48 (4.8%)	88 (4.2%)
	Follow-up period (years), mean (SD)	2.2 (1.28)	2.1 (1.25)	2.1 (1.26)	2.2 (1.27)
	Never treated, N (%)	962 (80.0%)	1,044 (86.6%)	881 (87.8%)	1,755 (83.0%

451

* These groups are not mutually exclusive. ** This is the primary physician specialty for the first claim with WD as the primary diagnosis. Due to limitations in the analysis of the

prevalent WD population, it cannot be inferred with certainty that it represents the first diagnosis.

1 2						
2 3 4	455					
5 6	456	Table 3: Crude and age-standard	ized WD period prevale	ence 2017–2019		
7 8 9			N	Prevale	ence per million (95% Cl)	
10		Crude prevalence (overall)	1,481		21.2 (20.1-22.3)	
11 12		Age				
13 14		0- <18	256		12.4 (10.9-14.0)	
15		18-<40	490		27.1 (24.7-29.5)	
16 17		40-<65	581		26.1 (24.0-28.2)	
18		65+	154		17.1 (14.4-19.8)	
19 20		Sex				
21 22		Male	697		21.2 (19.7-22.8)	
23		Female	784		21.1 (19.7-22.6)	
24 25		Region				
26		Northeast	344		24.1 (21.6-26.7)	
27 28		South	439		18.4 (16.7-20.1)	
29		Midwest	355		22.2 (19.9-24.5)	
30 31		West	319		21.6 (19.2-24.0)	
32 33					21.0 (19.2-24.0)	
34		Missing	24			
35 36		US-adjusted prevalence	1,481		22.0 (20.9-23.1)	
37	457	WHO-adjusted prevalence	1,481		21.4 (20.4-22.5)	
38 39	457 458	**Standardized to the age distribution ***Standardized to the age distributio	of the total world populat n of the total US population	ion in year 2000-2025, accord on in year 2010, according to	ling to WHO Census Bureau	
40 41	459					
42	460					
43 44	400					
45	461					
46 47						
48	462					
49 50						
51 52	463					
53	464					
54 55	TUT					
56	465					
57 58						
59 60	466					


Figure Legends

Figure 1: Distribution of WD subtypes by sex (a) and age (b)

Figure 2: Most frequent (Top-10) comorbidities of WD patients

to beet terien only

BMJ Open



Page 24 of 28

BMJ Open: first published as 10.1136/bmjopen-2024-089032 on 22 December 2024. Downloaded from http://bmjopen.bmj.com/ on June 7, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES)

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

BMJ Open




Figure 2: Most frequent (Top-10) comorbidities of WD patients

286x160mm (300 x 300 DPI)

Wilson Disease in the US - Epidemiology and Real-World Patient Characteristics Based on a Retrospective Observational Health Claims Database Study -Supplementary Materials


Supplementary Methods


Data source

Komodo Health is a healthcare technology company that has built an expansive Healthcare Map including de-identified claims (>65 billion clinical, pharmacy and lab encounters) for more than 320 million U.S. patients. These encounters represent census level representation across populations (e.g., age, geography, risk pools) in the United States (US), including hospital networks, physician networks, healthcare claim processing companies (i.e. claims clearinghouses), pharmacies, and health insurers. Nearly half of the data in Komodo's Healthcare Map is comprised of "closed" datasets, which come directly from the payer and provide insight regarding the complete patient journey, such as full medical and/or prescription benefit information, including insurance eligibility. Komodo's private payercomplete population contains prescription and/or medical claims of over 120 million individuals collected from 150+ private insurers in the US. Data that is rooted in a complete patient journey provides an optimal basis for a variety of research focuses, including adherence studies, treatment pattern studies and comparative effectiveness studies within an insured population.

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Supplementary Figures





Supplementary Figure 1. Distribution of hepatic, neurologic and psychiatric Wilson disease subtypes

Supplementary Tables

Supplementary Table 1. ICD-10 Codes for identification of hepatic Wilson disease subtype

	ICD-10 Code	Description
Elevated serum aminotransferases	R74	Nonspecific elevation of levels of transaminase and lactic acid dehydrogenase [LDH]
Acute hepatitis (not viral)	K72	Acute and subacute hepatic failure
Coagulopathy	D68	Coagulation defect, unspecified
Hepatic	5722	Hepatic encephalopathy
encephalopathy	K727	Hepatic encephalopathy
Cirrhosis	K717	Toxic liver disease with fibrosis and cirrhosis of liver
(decompensated or compensated)	5715	Cirrhosis of liver without mention of alcohol
compensated)	K74	Fibrosi and cirrhosis of liver
	K704	Alcoholic hepatic failure
	K711	Toxic liver disease with hepatic necrosis
Liver failure	K720	Acute and subacute hepatic failure
	K721	Chronic hepatic failure
	K729	Hepatic failure, unspecified
	18501	Esophageal varices with bleeding
Marianal	18511	Secondary esophageal varices with bleeding
Variceal hemorrhage	1983	Oesophageal varices with bleeding in diseases classified elsewhere
	4560	esophageal varices with bleeding
	45620	esophageal varices in diseases classifies elsewhere, with bleeding
Portal hypertension	K766	portal hypertension
	5723	portal hypertension
Hepatocellular carcinoma	C220	liver cell carcinoma

Supplementary Table 2. ICD-10 Codes for identification of neurological Wilson disease subtype

	ICD-10	
	Code	Description
	R251	tremor, unspecified
Tremor	G251	Drug-induced tremor
	G252	other specified forms of tremor
	G250	essential tremor

	3331	essential and other specified forms of tremor
	G20	parkinson's disease
	G219	secondary parkinsomism, unspecified
	G218	other secondary parkinsonism
	G2122	neuroleptic induced parkinsonism
	G214	vascular parkinsomism
Parkinsonism or	G2119	other drug induced secondary parkinsonism
akinetic rigid	3321	secondary parkinsonism
syndrome	G212	secondary parkinsonism dur to other external agents
	G213	postencephalitic parkinsonism
	G8903	Parkinson's disease mg
	G211	other drug induced secondary parkinsonism
	G22	Parkinsonism in diseases classified elsewhere
	G21	secondary parkinsonism
	R2689	other abnormalities of gait and mobility
	R269	unspecified abnormalities of gait and mobility
Gait abnormalities/ataxia	R26	abnormalities of gait and mobility
	R268	other abnormalities of gait and mobility
	R270	ataxia, unspecified
	78451	Dysarthria
Dysarthria	R471	Dysarthria and anarthria
Dysartinia	169222	Dysarthria following oth nontraumatic intrcrn hemorrhage
	169022	Dysarthria followin nontraumatic subarachnoid hemorrhage
	G249	Dystonia, unspecified
Dystonia	G248	Other dystonia
	G24	Dystonia
Pseudobulbar palsy	G1220	Motor neuron disease unspecified
r seuuunnai haisy	33523	Pseudobulbar palsy
	G40	Epilepsy and recurrent seizures
Seizures	F445	Conversion disorder with seizures or convulsions
	R568	Other and unspecified convulsions
Migraine	G43	Migraine
Somatoform autonomic dysfunction	F45	Somatoform disorders

1
2
3
4 5
5
5 6 7 8 9 10 11
/
8
9
10
11
12
12 13 14 15 16 17 18
14
15
16
1/
18
19
∠∪ 21
20 21 22 23 24 25 26 27 28 29 30 31 32 33
22
23
24
25
20
27 20
20 20
29
21
27
32 33
27
34 35
36
36 37
37 38
30 39
40
40 41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59

60

	G3184	Mild cognitive imparment, so stated
	F03	Unspecified dementia
Cognitive disorder	F05	Delirium due to known physiological condition
	F06	Other mental disorders due to known physiological condition
	331883	Mild cognitive imparment, so stated

Supplementary Table 3. ICD-10 Codes for identification of psychiatric Wilson disease subtype

	ICD-10 Code	Description
	F32	Major depressive disorder, single episode
Depression	F33	Major depressive disorder, recurrent
	F34	Persistent mood disorder
	F48	Nonpsychotic mental disorder, unspecified
	F40	Phobic anxiety disorder
	F41	Other anxiety disorder
Neuroses	F42	Obsessive compulsive disorder
	F43	Reaction to severe stress and adjustment disorders
	F44	Dissociative and conversion disorders
	F45	Somatoform disorders
	F29	Unspecified physchosis not due to substance or known psychological condition
	F20	Schizophrenia
	F21	schizotypal disorder
Psychosis	F22	delusional disorders
	F23	brief psychotic disorder
	F24	shared psychotic disorder
	F25	schizoaffective disorder
	F28	other psychotic disorder not due to a substance or known physioogical condition
	F07	Personality change due to known physiological condition
Personality changes	F60	Specific personality disorder
	F61	Mixed and other personality disorder
	F62	Enduring personality change
Bipolar disorder	F31	Bipolar affective disorder

BMJ Open

Wilson Disease in the US - Epidemiology and Real-World Patient Characteristics Based on a Retrospective Observational Health Claims Study

Journal:	BMJ Open
Manuscript ID	bmjopen-2024-089032.R2
Article Type:	Original research
Date Submitted by the Author:	27-Nov-2024
Complete List of Authors:	Fang, Shona; Alexion Pharmaceuticals Inc Strader, Carey; Oracle America Inc Costantino, Halley; Oracle America Inc Weiss, Karl Heinz; Salem Hospital Hedera, Peter; University of Louisville
Primary Subject Heading :	Epidemiology
Secondary Subject Heading:	Public health, Gastroenterology and hepatology, General practice / Family practice, Neurology
Keywords:	Prevalence, EPIDEMIOLOGY, Cross-Sectional Studies, Chronic Disease





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

terez oni

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies



Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

1	Wilson Disease in the US - Epidemiology and Real-World Patient
2	Characteristics Based on a Retrospective Observational Health
3	Claims Study
4	
5	Shona Fang, ScD ¹ Carey Strader, ² Halley Costantino, ² Karl Heinz Weiss, MD ³ Peter Hedera, MD,
6	PhD ⁴
7	¹ Alexion Pharmaceuticals Inc, Boston, MA; ² Oracle America Inc, Redwood Shores, CA; ³ Salem
8	Hospital, Heidelberg, Germany; ⁴ University of Louisville, Louisville, KY
9	ORCID: Peter Hedera 0000-0003-2699-4085, Halley Costantino 0009-0000-6658-6057
10	Corresponding author:
11	Shona Fang, ScD
12	121 Seaport Avenue
13	Boston, MA 02210
14	shona.fang@alexion.com
15	Word count: 3,648
16	Running title: Epidemiology of Wilson Disease in the US
17	Financial Disclosure/Conflict of Interest concerning the research related to the manuscript: CS and
18	HC declare being employees of Oracle America, which received funding from Alexion
19	Pharmaceuticals to conduct this study. PH has no financial relationships to disclose. KHW declares no
20	conflicts of interest that pertains to this work. SF is an employee of Alexion, AstraZeneca Rare
21	Disease and owns stock in AstraZeneca.

22 Funding Sources for study: This study was funded by Alexion Pharmaceuticals.

BMJ Open

1 2		
- 3 4	23	Abstract
5 6	24	Objectives: To describe the epidemiology, patient characteristics and comorbidities in patients with
7 8 9	25	Wilson disease (WD) in the US.
10 11 12	26	Design: Retrospective, population-based study
13 14	27	Setting: The study used the US Komodo claims database containing records regarding medical claims
15 16	28	for over 120 million individuals.
17 18 19	29	Participants: Patients with WD were identified via ICD-10 code during the study period 2016–2019
20 21	30	and no age restriction was applied. A further stratification by disease subtype ("hepatic", "neurologic"
22 23	31	and "psychiatric") was performed.
24 25 26	32	Main outcome measures: WD prevalence was reported by age, sex, and US census regions/divisions.
27 28	33	Adjusted prevalence was calculated using age-specific prevalence standardized to the US (2010 US
29 30	34	census) and to the world (WHO 2000-2025) to enable comparisons across countries, using direct
31 32 33	35	standardization of prevalence estimates by age group.
33 34 35	36	<i>Results:</i> Overall, 2,115 WD patients were identified during the study period. Among them, 56.8% had
36 37	37	hepatic symptoms, 57.0% neurologic symptoms and 47.4% psychiatric symptoms. The most frequent
38 39	38	manifestations in hepatic patients were liver signs and symptoms (90.8%), in neurologic patients
40 41	39	cognitive defects (50.7%), and in psychiatric patients mood disorders (86.4%). The mean age in the
42 43	40	overall cohort was 39.9 years. Prevalence estimation was based on 1,481 WD patients between 2017
44 45	41	and 2019. The 2017–2019 crude period prevalence was 21.2 patients per million (95% confidence
46 47 48	42	interval: 20.1–22.3), with similar prevalence observed for both sexes.
49 50	43	Conclusions: This study provides important real-world data on the diagnosed prevalence of WD in the
51 52	44	US and revealed the comorbidities associated with various disease subtypes, thereby providing a
53 54 55	45	comprehensive basis for guiding physicians and policy makers in the management of this chronic
56 57 58 59 60	46	disease.

1 2 3 4	47	Strengths and limitations of this study
5 6	48	• This study estimated the diagnosed prevalence of WD for the first time in the US, by using a
7 8	49	large, nationally representative claims database. The real-world nature of the data helps
9 10 11	50	estimate the observed frequency of Wilson disease in the US using ICD-10 codes specific to
11 12 13	51	WD.
14 15	52	• The classification of patients into subtypes, and especially the novel approach to differentiate
16 17	53	psychiatric symptoms from neurological symptoms, was a further strength of this study.
18 19	54	• Besides general limitations inherent to claims data, the limitations specific to this study
20 21	55	included a limited study period after the introduction of a new WD-specific ICD-10 code in
22 23	56	2015.
24 25 26	57	• The used claims data did not capture information on OTC medications and the treated patients
20 27 28	58	represented the proportion of patients with prescription treatment only.
28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 50 51 52 53 54 55 56 57 58 59 60	59	

Confidential - Oracle Restricted pr peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open

60 Introduction

Wilson disease (WD) is an autosomal recessive condition which leads to an excessive copper deposition in body organs, particularly in the liver and the central nervous system.¹ This genetic disorder is caused by mutations of the P-type ATPase copper transporter ATP7B gene located in the human chromosome 13.² To date, more than 600 variants in the ATP7B gene have been described, and most WD patients are compound heterozygous with two different ATP7B variants, complicating and prolonging genetic WD diagnosis.³ WD generally presents in childhood and young adulthood with the most common age of presentation between 10 and 20 years, though patients can occasionally present before the age of 5 years and after the age of 70 years.⁴

Clinical presentation of WD includes a combination of hepatic, neurologic, psychiatric, and ophthalmologic symptoms. Psychiatric symptoms often precede the diagnosis of WD and include personality changes, depression, cognitive changes, and anxiety.⁵ The neurologic symptoms of WD mostly refer to dysfunction in the extrapyramidal system including dysarthria, dystonia, gait abnormalities, tremor, parkinsonism, chorea, and seizures.⁶ Psychiatric symptoms have been only recently recognized as independent manifestations of WD, as it was previously assumed that they occur together with neurological symptoms, and patients were often referred to as having neuro-psychiatric disorders.⁷ The symptoms related to hepatic dysfunction in WD can range from an asymptomatic increase in liver enzyme levels to severe liver failure. Typically, early on in disease progression there is a mild increase in transaminases, which then may progress to chronic active hepatitis, followed by fibrosis and cirrhosis.⁸

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

WD is a rare disease with recent worldwide clinical prevalence estimates ranging from approximately 16.7 to 25 patients per million,⁹ although the prevalence can vary across countries and may be higher in selected regions such as in some Asian communities.¹⁰ Interestingly, there is a discrepancy of WD prevalence estimates originating from epidemiological compared to genetic studies and recent genetic data with a considerably higher prevalence (139 per million) indicate that the prevalence of WD may be underestimated.¹¹ The possibility of underdiagnosis, misdiagnosis and the lack of accounting for incomplete variant penetrance in the genetic calculations were hypothesized as the main reasons for

BMJ Open

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

the observed inconsistency between genetic vs. clinical data.^{11,12} For the US, population-based
epidemiological data are still scarce. A previous study reported a genetic birth prevalence of 18.2 per
million births,¹³ and an abstract on cardiac manifestations in WD reported a prevalence of 26 patients
per million, but no details of methodology.¹⁴

91 Thus, large population-based studies assessing the epidemiology of WD and its subtypes in the US are 92 needed, allowing for a greater characterization around the spectrum of disease severity and the 93 diagnosed prevalence of WD. Here we present data from a recently completed real-world evidence 94 study that used US claims data to investigate various aspects of WD in a real-life setting including 95 epidemiology and patient demographic and clinical characteristics.

96 Methods

97 Study design

This retrospective, population-based observational study used health insurance claims data to assess WD epidemiology and patient characteristics using the US Komodo Health claims database available from 2012–2020.¹⁵ Komodo's private payor-complete database contains records regarding prescription and/or medical claims for over 120 million individuals, collected from more than 150 private insurers in the US, including Medicaid managed-care and Medicare Advantage plans. This study used the closed claims available in the database. Closed claims come directly from the payer and provide the complete patient journey, such as full medical and/or prescription benefit information including insurance eligibility. For more details on the data source, see Supplementary Methods.

106 Population

Patients were selected based on their first observed WD diagnosis (index event) in the claims database
between 2016 and 2019 (study period). The diagnosis was based on code (ICD-10 code E83.01 or
ICD-9-CM code 275.1 prior to October 1, 2015). The standard ICD-9 diagnostic code for WD was not
specific to WD and could also include another rare condition called Menkes disease. The WD-specific
ICD-10 code (E83.01) was introduced in the US on October 1, 2015. A WD diagnosis was defined as
at least one inpatient or two outpatient visits with a WD ICD-10 code, separated by at least 30 days

BMJ Open

during the study period. For the selected WD patients a follow-up period of at least one calendar year (defined as post-index period) was examined, to observe their treatment journey. The follow-up period was defined from index until the last available claim. No age restriction was imposed. Patients were excluded from the study if they had at least one prescription for a copper replacement drug, a drug used to treat Menkes disease, during the study period.

118 Cohorts and subgroups

The cohort presented here includes patients that fulfilled the criteria for at least one WD diagnosis at any time during the study period (2016–2019) and a continuous enrollment for at least one calendar year before the index event. Separately, prevalence was assessed in the period between 2017 and 2019 for patients that had a history of at least one WD diagnosis at any time during that period and a continuous enrollment for at least two calendar years. This separate assessment period for prevalence estimation was based on the WD-specific diagnosis code becoming effective in the US only in 2015. Due to the possibility of miscoding, the most accurate prevalence estimation of WD can be made between 2017 and 2019, as this period includes at least one full calendar year since the introduction of the new code.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

A further stratification by WD subtypes was performed, according to ICD-10 codes (see Supplementary Tables 1-3) based on the presence of signs and symptoms for each category. The subtypes "hepatic", "neurologic" and "psychiatric" were not mutually exclusive or strictly delineated but were based on the presence of signs and symptoms. Patients were assigned to the hepatic subtype if they were diagnosed with liver signs and symptoms, acute hepatitis (not viral), cirrhosis (decompensated or compensated), liver failure, portal hypertension, or hepatocellular carcinoma. Patients assigned to the neurologic subtype had a diagnosis for tremor, parkinsonism or akinetic rigid syndrome, gait abnormalities/ataxia, dysarthria, dystonia, chorea, dysphagia, myopathy, seizures, migraine, somatoform autonomic dysfunction or cognitive disorder. Patients diagnosed with mood disorders, paranoia/schizophrenia, psychosis, or personality disorders were assigned to the psychiatric subtype.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

139 Variables

Data on patient characteristics (age, sex, region of residence) and physician specialty at baseline (i.e., at first observed WD diagnosis during the study period) were ascertained. In addition, the proportion of patients never treated and distribution of subtypes and manifestations were ascertained during the study period. Comorbidities /concurrent diagnoses were assessed during the study period (2016-2019). Overall, age-, sex-, and region-specific prevalence (crude and age-adjusted period prevalence) were assessed in the period between 2017 and 2019. A rationale for considering a period prevalence rather than an annual prevalence was that the identification of WD patients was based on ICD-10 codes, without considering WD treatment or laboratory records, and the assumption that WD patients who are well managed using over the counter (OTC) or prescription medication may not necessarily visit a health care provider (HCP) each year. A further reason for using a period prevalence was to account for possible misdiagnosis in the first year after the introduction of the ICD-10 code for WD.

151 Data analysis

Descriptive statistics were calculated for demographic and baseline characteristics (overall and by subtype). Means and standard deviations (SDs) were provided for continuous or discrete data. Frequencies and percentages were provided for categorical data. For WD manifestations, the frequencies of occurrence of specific ICD-10 codes within subtypes and within the overall patient cohort were calculated and the three most frequent manifestations were listed by subtype. For comorbidities, all recorded diagnoses (ICD-10 codes level-3) at any time during the study period were ranked according to frequency and a list of the 10 most frequent comorbidities in the overall cohort were reported. In addition, the Charlson Comorbidity index (CCI; version of 2011), an assessment tool designed to predict mortality in patients with multiple comorbidities,¹⁶ was assessed for each patient and a mean score including SD (higher scores indicating greater mortality risk and more severe comorbid conditions) was calculated for the overall cohort. Crude period prevalence was calculated from the number of WD cases identified and was expressed as patients per million including 95% confidence intervals (CI). The denominator was the number of patients with continuous enrollment spanning the period of interest (2017-2019) and the numerator was any patient from the denominator with at least one WD diagnosis claim during the period of interest. Prevalence was reported by age,

1		
2 3 4	167	sex, and US census regions/divisions. Adjusted prevalence was calculated using age-specific
5 6	168	prevalence standardized to the US (2010 US census) and to the world (WHO 2000-2025) to enable
7 8 9	169	comparisons across countries, using direct standardization of prevalence estimates by age group.
10 11	170	Ethics statement
12 13	171	This was study was approved by the IRB Pearl Pathways. The study was conducted in accordance
14 15	172	with legal and regulatory requirements, as well as with scientific purpose, value and rigor, and
16 17	173	followed generally accepted research practices described in Good Pharmacoepidemiology Practices
18 19 20	174	guidelines issued by the International Society for Pharmacoepidemiology.
21 22	175	Patient and public involvement
23 24 25	176	Patients or the public were not actively involved in this observational study.
26 27 28	177	Data availability statement
28 29 30	178	The data that support the findings of this study are available from Komodo Health. Restrictions apply
31 32	179	to the availability of these data, which were used under license for this study. Access to data must be
33 34	180	requested through Oracle.
35 36 37	181	Results
38 39	182	Baseline characteristics
40 41 42	183	The observed cohort included 2,115 WD patients identified between 2016 and 2019. Selected baseline
43 44	184	characteristics of the overall cohort and by subtype are displayed in Table 1 The mean age in the
45 46	185	overall cohort was 39.9 years (SD=20.1 years). The lowest mean age was reported for the psychiatric
47 48	186	subtype (39.2 years, SD=20.2 years) and the highest for the neurologic subtype (42.3 years, SD=20.7
49 50	187	years). Overall, 51.8% were male patients. A larger portion of patients came from the South (30.6%)
51 52	188	and fewer from the Northeast (21.8%) with little difference between subtypes. While for a majority
53 54	189	(54.2%) of overall WD cases no information was available regarding the specialists managing the
55 56 57	190	primary WD diagnosis, the available results showed that patients were mostly in the care of
57 58 50	191	gastroenterologists (13.2%) and general/family practitioners (12.6%). Hepatic patients were more
59 60	192	frequently seen by gastroenterologists (16.4%), as compared to the other subtypes (9.7% of neurologic

 BMJ Open

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

patients and 9.0% of psychiatric patients). On average, the follow-up time in the study was 2.2 years (SD=1.3 years) with little difference between subtypes. Among all patients, the majority (83.0%) were never treated with a reimbursable WD prescription medication during the study period. WD subtypes and manifestations Among the cohort, more than half had hepatic and/or neurologic symptoms (56.8% and 57.0%, respectively) and around half had psychiatric symptoms (47.4%). Most patients had overlapping subtypes, presenting concomitantly with hepatic, neurologic, and/or psychiatric signs and symptoms (see Supplementary Figure 1). For instance, 734 (34.7%) presented with at least two concomitant conditions, whereas 422 (20.0%) WD patients presented with the three of them together. Figure 1 illustrates the distribution of sex (a) and age (b) within subtypes. Slightly more male than female patients had neurologic (54.6%) and psychiatric (55.6%) symptoms, whereas the sex distribution was equal in the hepatic subtype. With regards to age distribution, most patients in all subtypes were in the age groups between 18 to 39 years and 40 to 64 years. The distribution of young (0-17 years) and older (above 65 years) patients was also similar between subtypes, though there were slightly more older patients in the neurologic subtype (21% vs. 16% [hepatic] and 17% [psychiatric]). The most frequent manifestations associated with the different subtypes and their proportion in the overall cohort are highlighted in Table 2. Hepatic patients most frequently experienced liver signs and symptoms (90.8%), cirrhosis (37.9%) and hepatitis (28.9%). Neurologic patients most frequently experienced cognitive defects (50.7%), ataxia and gait abnormalities (36.2%) and dysphagia (27.2%). Psychiatric patients most frequently experienced mood disorders (86.4%), a mix of symptoms in children (22.3%) and paranoia/schizophrenia (19.8%). **Comorbidities/Concurrent diagnoses** WD patients were diagnosed with a broad spectrum of comorbidities. The most common clinical conditions diagnosed during the study period included other joint disorders (50.9%), unspecified soft tissue disorders (49.3%), dorsalgia (49.1%), disorders of lipoprotein metabolism and other lipidemias (45.9%), essential hypertension (45.2%), anxiety disorders (42.9%), and other diseases of liver

BMJ Open

(40.0%), Figure 2. The extent of concurrent diagnoses and comorbidities was also reflected by a mean
CCI score of 1.92 (SD=2.68).

Prevalence estimation was based on 1,481 WD patients between 2017 and 2019. The 2017–2019 crude period prevalence was 21.2 patients per million (95% CI: 20.1–22.3), with similar prevalence observed for both sexes (male: 21.2 per million, 95% CI: 19.7-22.8 and female: 21.1 per million, 95% CI: 19.7–22.6), Table 3. The crude period prevalence peaked among young adults in the 18 to 39 years age group (27.1 per million, 95% CI: 24.7–29.5), followed closely by adults 40 to 64 years old (26.1 per million, 95% CI: 24.0–28.2). The highest crude period prevalence was recorded in the Northeast (24.1 per million, 95% CI: 21.6–26.7), followed by the Midwestern (22.2 per million, 95% CI: 19.9–24.5), Western (21.6 per million, 95% CI: 19.2–24.0), and Southern (18.4 per million, 95% CI: 16.7–20.1) regions of the US.

Adjusted period prevalence was calculated using age-specific prevalence standardized to the US (2010 US census) and to the world (WHO 2000-2025). Between 2017 and 2019, both the US-adjusted and WHO-adjusted period prevalences were similar (22.0 per million, 95% CI: 20.9–23.1 and 21.4 per million, 95% CI: 20.4–22.5, respectively) to the crude period prevalence observed in this study.

³⁹ 235 **Discussion**

4142 236 Principal findings and implications

There is a gap of knowledge regarding the epidemiology and clinical characteristics of WD patients
from a national and international perspective. In this large population-based study we assessed WD
patient characteristics and epidemiology in the US.

- Approximately two-thirds of the cohort showed hepatic and/or neurologic symptoms, which is
 Approximately two-thirds of the cohort showed hepatic and/or neurologic symptoms, which is
- 53 241 consistent with the natural disease course, as WD mostly affects the liver and brain.¹⁷ Typically,

hepatic symptoms precede the onset of neurologic symptoms and may thus be diagnosed at a younger hepatic symptom precede the onset of neurologic symptoms and may thus be diagnosed at a younger

 $\frac{57}{58}$ 243 age². In line with this, though not as evident in the age distribution by subtypes, the mean age at index

in the hepatic subtype was slightly lower compared to the neurologic subtype. In agreement with our

BMJ Open

data on sex distribution in the neurologic and psychiatric subtypes, a registry-based study observed

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

that the neuropsychiatric WD form occurred more frequently in men (67%) vs. women (49%).¹⁸ Our results also revealed the extent of comorbidities associated with various disease subtypes, as some of the most frequently reported manifestations were quite severe (e.g., around 40% of patients in the hepatic subtype presented with cirrhosis). The frequency of hepatic, neurologic, and psychiatric presentations, as well as the manifestations within these subtypes varies considerably in other published studies.⁴ Considering the great variability in WD symptoms, it is likely that there is referral bias. A review of several independent case series suggested that dysarthria, gait abnormality/ataxia and dystonia are the most frequent manifestations in the neurologic subtype, which partially reflects our findings.⁴ The higher rates of dystonia and dysarthria reported in the literature may be explained by the fact that only symptomatic conditions that require treatment get captured in the claims under the ICD-10 diagnosis code. Furthermore, a study from China reported distributions of hepatic manifestations (e.g., 22% cirrhosis and 11% cirrhotic complications) which were similar to our findings.¹⁹ WD patients in our study were in the typical age range for first symptom onset and disease progression (between the second and sixth decade of life). We found a slightly lower mean age in the psychiatric subtype compared to the other subtypes, which might reflect that psychiatric manifestations are often the first symptoms.⁷ The earlier diagnosis of psychiatric WD may highlight a critical gap in care for these patients, as neurologic and psychiatric involvements have been previously assessed in tandem, with neurologic symptoms becoming more apparent later in life. Given the recessive nature of WD, the results confirmed the expectation of a relatively even distribution of cases across sexes, which also aligns with previous studies conducted in France,²⁰ and Hong Kong.¹⁹ The geographical distribution within the US, with a larger portion of patients coming from the South and fewer from the Northeast, might correspond to the distribution of major university centres in the US where WD patients are typically diagnosed. Given the nature of the disease, it is not surprising that patients were primarily in the care of gastroenterologists (most pronounced in hepatic patients), though a considerable fraction of patients was also diagnosed or treated by general or family practitioners who might be the first contact points. The high rate of patients never treated with a reimbursable WD medication during the study

BMJ Open

period was likely due to the use of OTC zinc preparations which are not covered by insurers in the US, the refusal to take medications and rely solely on a low-copper diet, or the hypothesis that some physicians used the WD diagnosis code to initiate further testing for the patients but did not prescribe a WD medication at that initial stage. Further investigation on this aspect is warranted given the chronic nature of this disease. Furthermore, our results demonstrated that WD patients were diagnosed with a broad spectrum of comorbidities, most frequently affecting joints, soft tissues, and the cardiovascular system, as well as pain symptoms and metabolic disorders. Comorbidities of WD are rarely described in the literature and vary considerably, however, our findings are at least partially consistent with comorbidities reported in the literature. Kruger et al and Dziezyc et al described that the most common complications in WD patients were pain, renal, neurologic, cardiac, skin, osteoarticular, or endocrinologic complications and included other organ disturbances. ^{21,22} Only a few population-based studies assessing WD epidemiology have been performed to date world-wide. It is challenging to compare the results from this study to other reports, because of the heterogeneity of the disease and of the heterogeneity in population, diagnosis, and methodologies employed in other studies assessing WD epidemiology. However, the observed prevalence estimates (US-adjusted prevalence: 22.0 patients per million) align well within the WD prevalence range reported in other claims-based studies in France (15 per million), ²³ and China (17.9 per million), ¹⁹ while estimates from a claims-based study in South Korea were slightly higher (38.7 per million).²⁴ Two recent systematic literature reviews assessed WD prevalence data originating from populationbased epidemiological as well as genetic studies.^{11,25} Sandahl et al. reported a crude population-based prevalence between 25 and 34.5 per million,²⁵ and underlined that specific populations in Croatia, Sardinia, Israel, Costa Rica, Middle Eastern countries, Pakistan and India had considerably higher prevalence estimates, either related to consanguinity or higher mutation frequencies. Gao et al. performed a meta-analysis resulting in a pooled population-based prevalence of 14 patients per million.¹¹ Both reviews mentioned that at least in some studies a higher genetic vs. clinically based prevalence could be observed. Gao et al. reported a pooled prevalence at birth of 127 per million.¹¹

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Overall, it seems evident that many factors such as the still uncertain mutational spectrum and penetrance of WD variants, the unclear effect of combined mutations and epigenetic factors, methodological differences in studies, underdiagnosis, changes in diagnostic awareness and treatment options over time, as well as geographic factors may influence WD prevalence estimates. Thus, it is important to assess epidemiological data from large, population-based studies, as the one presented here.

305 Strengths and limitations

This study benefitted from several strengths. Data elements extracted from claims, some of which are not generally available in literature or patient registries, are collected routinely in clinical practice and represent real-world activities and outcomes. The real-world nature of the data helps estimate the observed frequency of diagnosed diseases using ICD-10 codes. The ICD-10 codes for WD are highly specific, despite any limitations in coding or misdiagnosis which may occur. The Komodo claims data are large and nationally representative based on comparisons made to the US census estimates (by age, sex, and region). The closed claims provide a longitudinal history that facilitates the analysis of the natural history of the disease, healthcare utilization, and treatment dynamics. Of note, the crude prevalence observed in this study between 2017 and 2019 was comparable to the US age-standardized adjusted results, reaffirming the representativeness of the Komodo data for rare disease research in the US. The classification of patients into subtypes, and especially the novel approach to differentiate psychiatric symptoms from neurological symptoms, was a further strength of this study.

There are some general limitations inherent to claims data, such as the potential for errors in diagnosis coding or record keeping at the point of the HCP. Since claims data are used for billing purposes, they only include records for the insured population, therefore projections of the US population assume similarities between the insured and uninsured patients. Leveraging secondary data requires an algorithm for case identification and validated algorithms specific to WD do not currently exist. Claims data contain only reimbursed medical services and thus e.g., results of lab tests or patientreported outcomes are not captured. In addition, these claims data in general have limited follow-up,

BMJ Open

325 e.g., due to patients switching insurance plan or losing coverage or privacy restrictions limiting data326 linkage.

In addition, there were some limitations specific to this study. Epidemiological trends over time were hard to assess given the limited study period and the introduction of the new WD-specific ICD-10 code. Only symptomatic conditions were captured under the ICD-10 code; therefore, no inferences can be made regarding pre-symptomatic patients with WD. The claims data did not capture information on laboratory testing well, and results are not available in claims data. Further the claims data did not capture OTC medications and thus the treated patients represented the proportion of patients with prescription treatment only. The proportion of patients without a claim for a WD-specific treatment was quite high and unexpected however and whether this truly reflects a large proportion of patients on OTC zinc is unclear. Further investigation is needed as to the proportion of WD patients receiving treatment in the US.

337 Conclusions

This claims study provides important real-world data on the prevalence of WD in the US and revealed the extent of comorbidities associated with various disease subtypes. The results of this study extend existing research findings and provide a comprehensive epidemiological basis for guiding physicians and policy makers in the management of this chronic disease. Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

BMJ Open

1		
2 3 4	343	Declarations
5 6 7	344	Acknowledgments
7 8 9	345	Medical writing was provided by Dr. Sophia von Stockum of ZEG – Berlin Center for Epidemiology
10 11 12	346	and Health Research GmbH with editorial input from all authors.
12 13 14	347	Authors' Contributions
15 16	348	SF, CS, KHW and PH were responsible for the design, writing and editing of the final version of the
17 18	349	manuscript. SF, CS and HC were responsible for the execution of the study and HC was responsible
19 20	350	for the analysis of the data. SF is the guarantor. All authors had critically reviewed the manuscript and
21 22 23	351	approved its final version.
24 25	352	Financial Disclosures of all authors (for the preceding 12 months)
26 27	353	PH has no financial relationships to disclose. KHW advises for Alexion, Univar, Orphalan, Desitin,
28 29	354	Tilomed, Ultragenyx, Pfizer, Vivet therapeutics, Abbvie. HC is an employee of Oracle America,
30 31 32	355	which has provided consultancy for Alexion Pharmaceuticals.
33 34	356	Financial Disclosures
35 36 37	357	PH has no financial relationships to disclose. KHW declares no conflicts of interest that pertains to
38 39	358	this work. SF is an employee of Alexion, AstraZeneca Rare Disease and may own stock in
40 41	359	AstraZeneca.
42 43 44	360	AstraZeneca.
45 46 47	361	
48 49 50	362	
51 52	363	
53 54 55	364	
56 57 58 59 60	365	

366	R	eferences
367	1	Moini M, To U, Schilsky ML. Recent advances in Wilson disease. Transl Gastroenterol Hepatol
	1	2021; 6:21. <u>https://doi.org/10.21037/tgh-2020-02</u> .
	2	Kasztelan-Szczerbinska B, Cichoz-Lach H. Wilson's Disease: An Update on the Diagnostic
	-	Workup and Management. J Clin Med 2021; 10(21). https://doi.org/10.3390/jcm10215097.
	3	Ferenci P. Regional distribution of mutations of the ATP7B gene in patients with Wilson disease:
	5	impact on genetic testing. Hum Genet 2006; 120(2):151–59. <u>https://doi.org/10.1007/s00439-006-</u>
		0202-5.
	4	Mulligan C, Bronstein JM. Wilson Disease: An Overview and Approach to Management. Neurol
		Clin 2020; 38(2):417–32. <u>https://doi.org/10.1016/j.ncl.2020.01.005</u> .
376	5	Akil M, Schwartz JA, Dutchak D, Yuzbasiyan-Gurkan V, Brewer GJ. The psychiatric
377		presentations of Wilson's disease. J Neuropsychiatry Clin Neurosci 1991; 3(4):377–82.
378		https://doi.org/10.1176/jnp.3.4.377.
379	6	WILSON SAK. PROGRESSIVE LENTICULAR DEGENERATION: A FAMILIAL NERVOUS
380		DISEASE ASSOCIATED WITH CIRRHOSIS OF THE LIVER. Brain 1912; 34(4):295–507.
381		https://doi.org/10.1093/brain/34.4.295.
382	7	Zimbrean PC, Schilsky ML. Psychiatric aspects of Wilson disease: a review. Gen Hosp Psychiatry
383		2014; 36(1):53-62. https://doi.org/10.1016/j.genhosppsych.2013.08.007.
384	8	Boga S, Ala A, Schilsky ML. Hepatic features of Wilson disease. Handb Clin Neurol 2017;
385		142:91-99. https://doi.org/10.1016/B978-0-444-63625-6.00009-4.
386	9	Sandahl TD, Ott P. Epidemiology of Wilson Disease. In: Weiss K-H, Schilsky ML. Eds. Wilson
		disease. Pathogenesis, molecular mechanisms, diagnosis, treatment and monitoring. Amsterdam:
		Academic Press, 2018; p85–94.
	10	Yamaguchi H, Nagase H, Tokumoto S, et al. Prevalence of Wilson disease based on genome
		databases in Japan. Pediatrics international : official journal of the Japan Pediatric Society 2021;
		63(8):918–22. <u>https://doi.org/10.1111/ped.14565</u> .
	11	Gao J, Brackley S, Mann JP. The global prevalence of Wilson disease from next-generation
		sequencing data. Genet Med 2019; 21(5):1155–63. <u>https://doi.org/10.1038/s41436-018-0309-9</u> .
	12	Coffey AJ, Durkie M, Hague S, et al. A genetic study of Wilson's disease in the United Kingdom.
	10	Brain 2013; 136(Pt 5):1476–87. <u>https://doi.org/10.1093/brain/awt035</u> .
	13	Olivarez L, Caggana M, Pass KA, Ferguson P, Brewer GJ. Estimate of the frequency of Wilson's
		disease in the US Caucasian population: a mutation analysis approach. Annals of human genetics
	14	2001; 65(5):459–63. <u>https://doi.org/10.1046/j.1469-1809.2001.6550459.x</u> .
	14	Li XJ, Tunio NA, Rana MN, Al-Kindi S, Mansoor E, Sclair S. S1095 Prevalence of Cardiac
		Diseases in Wilson's Disease: A National, Population-Based Study. Am J Gastroenterol 2020; 115(1):S553-S553. https://doi.org/10.14309/01.ajg.0000706428.74725.f8.
	15	Komodo Health. <u>https://www.komodohealth.com/</u> (accessed Sep 13, 2023).
		Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and
	10	score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J
		Epidemiol 2011; 173(6):676–82. https://doi.org/10.1093/aje/kwq433.
	17	Członkowska A, Schilsky ML, eds. Handbook of Clinical Neurology : Wilson Disease. Elsevier,
	1,	2017.
	18	Litwin T, Gromadzka G, Członkowska A. Gender differences in Wilson's disease. Journal of the
		Neurological Sciences 2012; 312(1-2):31–35. <u>https://doi.org/10.1016/j.jns.2011.08.028</u> .
	19	Cheung K-S, Seto W-K, Fung J, Mak L-Y, Lai C-L, Yuen M-F. Epidemiology and natural history
411		of Wilson's disease in the Chinese: A territory-based study in Hong Kong between 2000 and 2016.
412		World J Gastroenterol 2017; 23(43):7716–26. https://doi.org/10.3748/wjg.v23.i43.7716.
413	20	Poujois A, Woimant F. Wilson's disease: A 2017 update. Clinics and research in hepatology and
414		gastroenterology 2018; 42(6):512–20. https://doi.org/10.1016/j.clinre.2018.03.007.
	367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413	$\begin{array}{cccccccccccccccccccccccccccccccccccc$

2			
3	415	21	Kruger E, Nedzesky J, Thomas NA, Cataldo J. PRO72 Common and Serious Comorbidities
4	416		Among Adults with Wilson Disease. Value in Health 2021; 24:S211.
5 6	417		https://doi.org/10.1016/j.jval.2021.04.1057.
6	418	22	Dzieżyc K, Litwin T, Członkowska A. Other organ involvement and clinical aspects of Wilson
7	419	22	disease. Handb Clin Neurol 2017; 142:157–69. https://doi.org/10.1016/B978-0-444-63625-
8 9	420		6.00013-6.
9 10	421	22	Poujois A, Woimant F, Samson S, Chaine P, Girardot-Tinant N, Tuppin P. Characteristics and
11	421	23	prevalence of Wilson's disease: A 2013 observational population-based study in France. Clinics
12	422		
13			and research in hepatology and gastroenterology 2018; 42(1):57–63.
14	424	24	https://doi.org/10.1016/j.clinre.2017.05.011
15	425	24	Choe EJ, Choi JW, Kang M, et al. A population-based epidemiology of Wilson's disease in South
16	426		Korea between 2010 and 2016. Sci Rep 2020; 10(1):14041. <u>https://doi.org/10.1038/s41598-020-</u>
17	427		<u>70976-1</u> .
18	428	25	Sandahl TD, Laursen TL, Munk DE, Vilstrup H, Weiss KH, Ott P. The Prevalence of Wilson's
19 20	429		Disease: An Update. Hepatology (Baltimore, Md.) 2020; 71(2):722-32.
20 21	430		https://doi.org/10.1002/hep.30911.
22	431		
23			
24	432		
25			
26	433		
27			
28	42.4		
29	434		
30 31			
32	435		https://doi.org/10.1002/hep.30911.
33			
34	120		
35	436		
36			
37	437		
38			
39 40	120		
41	438		
42			
43	439		
44			
45	440		
46	440		
47			
48 49	441		
49 50			
51	442		
52	442		
53			
54	443		
55			
56	444		
57 58	 -		
58 59			
60	445		

Tables

Table 1: Selected baseline characteristics of WD patients, overall and by subtype

7					
8		Hepatic*	Neurologic*	Psychiatric*	Overall
9		N=1,202	N=1,206	N=1,003	N=2,115
10	Age at index date (years), mean (SD)	40.4 (19.08)	42.3 (20.70)	39.2 (20.19)	39.9 (20.06)
11 12			, , , , , , , , , , , , , , , , , , ,	, , , , , , , , , , , , , , , , , , ,	, , , , , , , , , , , , , , , , , , ,
12					
14	Male , N (%)	607 (50.5%)	659 (54.6%)	558 (55.6%)	1,096 (51.8%)
15	US Region of residence at index, N (%)				
16					
17	Northeast	254 (21.1%)	246 (20.4%)	182 (18.2%)	462 (21.8%)
18					
19 20	South	376 (31.3%)	398 (33.0%)	332 (33.1%)	647 (30.6%)
20	Midwest	275 (22.9%)	292 (24.2%)	249 (24.8%)	502 (23.7%)
22		273 (22.376)	232 (2112/0)	213 (2110/0)	562 (25.776)
23	West	297 (24.7%)	270 (22.4%)	240 (23.9%)	504 (23.8%)
24					
25	Physician specialty of primary WD diagnosis, N (%)**	\sim			
26					
27 28	Gastroenterology	197 (16.4%)	117 (9.7%)	90 (9.0%)	279 (13.2%)
20 29					
30	General / Family Practice	136 (11.3%)	133 (11.0%)	124 (12.4%)	266 (12.6%)
31	Ophthalmology / Optometry	61 (5.1%)	59 (4.9%)	50 (5.0%)	101 (4.8%)
32	Ophthalmology / Optometry	01 (5.1%)	59 (4.9%)	50 (5.0%)	101 (4.8%)
33	Neurology	41 (3.4%)	75 (6.228%)	48 (4.8%)	88 (4.2%)
34 25					
35 36	Follow-up period (years), mean (SD)	2.2 (1.28)	2.1 (1.25)	2.1 (1.26)	2.2 (1.27)
37	Never treated, N (%)	062 (80.0%)	1 044 (96 69/)	001 (07 00/)	1 755 (92 00/)
38	Never treated, N (%)	962 (80.0%)	1,044 (86.6%)	881 (87.8%)	1,755 (83.0%)
	4.4.0	1			

* These groups are not mutually exclusive.

** This is the primary physician specialty for the first claim with WD as the primary diagnosis. Due to limitations in the analysis of the

450 prevalent WD population, it cannot be inferred with certainty that it represents the first diagnosis.

Ν

% subtype

% overall cohort (N=2,115)

Table 2: Most frequent (Top-3) WD manifestations by subtype

Manifestations

	Hepatic subtype* (N=1,202)				
	Liver signs and symptoms	1,092	90.8%	51.6%	
	Cirrhosis	456	37.9%	21.6%	
	Hepatitis	347	28.9%	16.4%	
	Neurologic subtype* (N=1,206)				
	Cognitive defects	611	50.7%	28.9%	
	Ataxia and gait abnormalities	436	36.2%	20.6%	
	Dysphagia	328	27.2%	15.5%	
	Psychiatric subtype* (N=1,003)				
	Mood disorders	867	86.4%	41.0%	
	Mix of symptoms, children	224	22.3%	10.6%	
	Paranoia and schizophrenia	199	19.8%	9.4%	
454	* These groups are not mutually exclusive.				
455					

456 *Table 1:* Crude and age-standardized WD period prevalence 2017–2019

		N	Prevalence per million (95% CI)
	Crude prevalence (overall)	1,481	21.2 (20.1-22.3)
	Age		
	0- <18	256	12.4 (10.9-14.0)
	18-<40	490	27.1 (24.7-29.5)
	40-<65	581	26.1 (24.0-28.2)
	65+	154	17.1 (14.4-19.8)
	Sex		
	Male	697	21.2 (19.7-22.8)
	Female	784	21.1 (19.7-22.6)
	Region		х <i>У</i>
	Northeast	344	24.1 (21.6-26.7)
	South	439	18.4 (16.7-20.1)
	Midwest	355	22.2 (19.9-24.5)
	West	319	21.6 (19.2-24.0)
	Missing	24	
	US-adjusted prevalence	1,481	22.0 (20.9-23.1)
	WHO-adjusted prevalence	1,481	21.4 (20.4-22.5)
57 58 59	**Standardized to the age distribution of ***Standardized to the age distribution o	the total world population in f the total US population in	n year 2000-2025, according to WHO year 2010, according to Census Bureau
60			
-			
62			
63			
64			
65			
66			


Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

Figure Legends

Figure 1: Distribution of WD subtypes by sex (a) and age (b)

Figure 2: Most frequent (Top-10) comorbidities/concurrent diagnoses of WD patients

BMJ Open



Page 24 of 28

BMJ Open: first published as 10.1136/bmjopen-2024-089032 on 22 December 2024. Downloaded from http://bmjopen.bmj.com/ on June 7, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES)

Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies

BMJ Open




Figure 2: Most frequent (Top-10) comorbidities/concurrent diagnoses of WD patients

286x160mm (300 x 300 DPI)

Wilson Disease in the US - Epidemiology and Real-World Patient Characteristics Based on a Retrospective Observational Health Claims Database Study -Supplementary Materials


Supplementary Methods


Data source

Komodo Health is a healthcare technology company that has built an expansive Healthcare Map including de-identified claims (>65 billion clinical, pharmacy and lab encounters) for more than 320 million U.S. patients. These encounters represent census level representation across populations (e.g., age, geography, risk pools) in the United States (US), including hospital networks, physician networks, healthcare claim processing companies (i.e. claims clearinghouses), pharmacies, and health insurers. Nearly half of the data in Komodo's Healthcare Map is comprised of "closed" datasets, which come directly from the payer and provide insight regarding the complete patient journey, such as full medical and/or prescription benefit information, including insurance eligibility. Komodo's private payercomplete population contains prescription and/or medical claims of over 120 million individuals collected from 150+ private insurers in the US. Data that is rooted in a complete patient journey provides an optimal basis for a variety of research focuses, including adherence studies, treatment pattern studies and comparative effectiveness studies within an insured population.

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Supplementary Figures





Supplementary Figure 1. Distribution of hepatic, neurologic and psychiatric Wilson disease subtypes

Supplementary Tables

Supplementary Table 1. ICD-10 Codes for identification of hepatic Wilson disease subtype

	ICD-10 Code	Description
Elevated serum aminotransferases	R74	Nonspecific elevation of levels of transaminase and lactic acid dehydrogenase [LDH]
Acute hepatitis (not viral)	K72	Acute and subacute hepatic failure
Coagulopathy	D68	Coagulation defect, unspecified
Hepatic	5722	Hepatic encephalopathy
encephalopathy	K727	Hepatic encephalopathy
Cirrhosis	K717	Toxic liver disease with fibrosis and cirrhosis of liver
(decompensated or compensated)	5715	Cirrhosis of liver without mention of alcohol
compensated)	K74	Fibrosi and cirrhosis of liver
	K704	Alcoholic hepatic failure
	K711	Toxic liver disease with hepatic necrosis
Liver failure	K720	Acute and subacute hepatic failure
	K721	Chronic hepatic failure
	K729	Hepatic failure, unspecified
	18501	Esophageal varices with bleeding
Marianal	18511	Secondary esophageal varices with bleeding
Variceal hemorrhage	1983	Oesophageal varices with bleeding in diseases classified elsewhere
	4560	esophageal varices with bleeding
	45620	esophageal varices in diseases classifies elsewhere, with bleeding
Portal hypertension	K766	portal hypertension
	5723	portal hypertension
Hepatocellular carcinoma	C220	liver cell carcinoma

Supplementary Table 2. ICD-10 Codes for identification of neurological Wilson disease subtype

	ICD-10	
	Code	Description
	R251	tremor, unspecified
Tremor	G251	Drug-induced tremor
	G252	other specified forms of tremor
	G250	essential tremor

	3331	essential and other specified forms of tremor
	G20	parkinson's disease
	G219	secondary parkinsomism, unspecified
	G218	other secondary parkinsonism
	G2122	neuroleptic induced parkinsonism
	G214	vascular parkinsomism
Parkinsonism or	G2119	other drug induced secondary parkinsonism
akinetic rigid	3321	secondary parkinsonism
syndrome	G212	secondary parkinsonism dur to other external agents
	G213	postencephalitic parkinsonism
	G8903	Parkinson's disease mg
	G211	other drug induced secondary parkinsonism
	G22	Parkinsonism in diseases classified elsewhere
	G21	secondary parkinsonism
	R2689	other abnormalities of gait and mobility
	R269	unspecified abnormalities of gait and mobility
Gait abnormalities/ataxia	R26	abnormalities of gait and mobility
	R268	other abnormalities of gait and mobility
	R270	ataxia, unspecified
	78451	Dysarthria
Dysarthria	R471	Dysarthria and anarthria
2 j ca c m a	169222	Dysarthria following oth nontraumatic intrcrn hemorrhage
	169022	Dysarthria followin nontraumatic subarachnoid hemorrhage
	G249	Dystonia, unspecified
Dystonia	G248	Other dystonia
	G24	Dystonia
Pseudobulbar palsy	G1220	Motor neuron disease unspecified
i seuuusuisai paisy	33523	Pseudobulbar palsy
	G40	Epilepsy and recurrent seizures
Seizures	F445	Conversion disorder with seizures or convulsions
	R568	Other and unspecified convulsions
Migraine	G43	Migraine
Somatoform autonomic dysfunction	F45	Somatoform disorders

1
2
3
4 5
5
5 6 7 8 9 10 11
/
8
9
10
11
12
12 13 14 15 16 17 18
14
15
16
1/
18
19
∠∪ 21
20 21 22 23 24 25 26 27 28 29 30 31 32 33
22
23
24
25
20
27 20
20 20
29
21
27
32 33
27
34 35
36
36 37
37 38
30 39
40
40 41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59

60

	G3184	Mild cognitive imparment, so stated
	F03	Unspecified dementia
Cognitive disorder	F05	Delirium due to known physiological condition
	F06	Other mental disorders due to known physiological condition
	331883	Mild cognitive imparment, so stated

Supplementary Table 3. ICD-10 Codes for identification of psychiatric Wilson disease subtype

	ICD-10 Code	Description
	F32	Major depressive disorder, single episode
Depression	F33	Major depressive disorder, recurrent
	F34	Persistent mood disorder
	F48	Nonpsychotic mental disorder, unspecified
	F40	Phobic anxiety disorder
	F41	Other anxiety disorder
Neuroses	F42	Obsessive compulsive disorder
	F43	Reaction to severe stress and adjustment disorders
	F44	Dissociative and conversion disorders
	F45	Somatoform disorders
	F29	Unspecified physchosis not due to substance or known psychological condition
	F20	Schizophrenia
	F21	schizotypal disorder
Psychosis	F22	delusional disorders
,	F23	brief psychotic disorder
	F24	shared psychotic disorder
	F25	schizoaffective disorder
	F28	other psychotic disorder not due to a substance or known physioogical condition
	F07	Personality change due to known physiological condition
Personality changes	F60	Specific personality disorder
	F61	Mixed and other personality disorder
	F62	Enduring personality change
Bipolar disorder	F31	Bipolar affective disorder